Bispecific antibody
A bispecific antibody targeting IL-18 and IL-13 effectively neutralizes both cytokines, addressing the limitations of current therapies by reducing inflammation and restoring immune balance in diseases like atopic dermatitis.
Patent Information
- Application Number
- PCT/GB2026/050775
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Current therapies targeting IL-18 and IL-13 individually have shown limited success due to their complex and overlapping roles in immune pathways, necessitating a more effective approach to neutralize both cytokines simultaneously to treat diseases like atopic dermatitis, asthma, and inflammatory bowel disease.
Development of a bispecific antibody that binds and neutralizes both IL-18 and IL-13, utilizing various technologies such as controlled Fab-arm exchange, Duobody, CrossMab, and WuxiBody to generate antibodies with specific antigen-binding domains for dual targeting.
The bispecific antibody reduces excessive inflammation and restores immune balance, offering superior clinical outcomes compared to monoclonal antibodies, with potential applications in inflammatory diseases and autoimmune conditions.
Smart Images

Figure GB2026050775_12112026_PF_FP_ABST
Abstract
Description
[0001] Bispecific Antibody
[0002] The invention relates to bispecific antibodies, and particularly to antibodies that specifically bind to IL-18 and IL-13. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the antibodies, for example in therapy and diagnosis. More specifically, the invention pertains to a bispecific antibody that targets IL-18 and IL-13 and can be used for the treatment of diseases associated with excessive or dysregulated IL-18 and IL-13 activity, including atopic dermatitis, asthma and inflammatory bowel disease (IBD).
[0003] Interleukin-18 (IL-18) and Interleukin-13 (IL-13) are critical cytokines involved in immune regulation and inflammation, playing significant roles in the pathogenesis of various diseases, including autoimmune disorders, chronic inflammatory conditions, atopic dermatitis, and certain cancers. IL-18 primarily promotes the activation of immune cells, particularly T cells and natural killer (NK) cells, and has been implicated in the development of Thl-driven immune responses (Landy et al., 2024). IL-13, on the other hand, is associated with Th2 immune responses, driving processes like allergic inflammation, fibrosis, and tissue remodelling (Bernstein et al., 2023).
[0004] Atopic dermatitis (AD), a chronic inflammatory skin disorder, is a prime example of a disease where IL-13 plays a central role in driving the inflammation and skin barrier dysfunction characteristic of the condition. IL-13 induces the production of IgE, a key factor in allergic reactions, and promotes the activation of eosinophils, mast cells, and other inflammatory cells that contribute to the persistent itching, redness, and skin damage observed in AD (Dubin et al., 2021). Additionally, IL-18 has been implicated in exacerbating inflammatory responses in skin conditions, contributing to both the initiation and persistence of inflammation in AD and other chronic skin diseases (Wang et al., 2023).
[0005] In diseases like AD, asthma, inflammatory bowel disease (IBD), and certain cancers, both IL-18 and IL-13 contribute to heightened inflammation, tissue damage, and immune dysregulation. Despite efforts to target these cytokines individually, current therapies have shown limited success due to their complex and overlapping roles in immune pathways. Moreover, these cytokines often operate in redundant or complementary pathways, where targeting one alone may not be sufficient to achieve optimal therapeutic outcomes.The development of bispecific antibodies (BsAbs) has emerged as a promising therapeutic strategy to address this challenge. A bispecific antibody that simultaneously targets IL-18 and IL-13 would offer a novel approach by neutralizing the activity of both cytokines at once, providing an orthogonal therapeutic effect. This dual targeting could enhance the efficacy of treatment by reducing inflammation and tissue damage across a broader range of disease pathways, making it particularly valuable in conditions like atopic dermatitis, where both cytokines play key roles in disease progression.
[0006] There is, therefore, the need for improved compositions for targeting IL-18 and IL-13 and treating diseases mediated by these two cytokines.
[0007] This invention pertains to a novel IL- 18 / IL-13 bispecific antibody designed to bind and neutralize both IL-18 and IL-13. By targeting both cytokines, the antibody has the potential to reduce excessive inflammation, alleviate symptoms of chronic diseases such as atopic dermatitis, and restore immune balance. The dual targeting approach may offer superior clinical outcomes compared to monoclonal antibodies targeting either cytokine alone, while minimizing the risk of adverse effects associated with off-target activity. In addition to its therapeutic potential in atopic dermatitis, this bispecific antibody may have broader applications in other inflammatory diseases, autoimmune conditions, and cancers, where dysregulation of IL-18 and IL-13 contributes to disease pathology.
[0008] Accordingly, in a first aspect of the invention, there is provided a bispecific antibody or antigen-binding fragment thereof, comprising a first antigen-binding domain that specifically binds to Interleukin-18 (IL-18) or a functional fragment or variant thereof, and a second antigen-binding domain that specifically binds to Interleukin-13 (IL-13) or a functional fragment or variant thereof.
[0009] As shown in the Examples, the inventors have developed bispecific antibodies that are capable of binding to IL-18 and IL-13, or a functional fragment or variant thereof, and inhibiting IL-18 and IL-13 function. The six CDR, VH, VL, CH and CL sequences of the first (IL-18) and second (IL-13) antigen-binding domains are summarised in the table shown in Figure 12. The inventors have used several different technologies to generate these bispecific antibodies, including controlled Fab-arm exchange (cFAE), Duobody, CrossMab, and WuxiBody. Accordingly, with reference to Figure 12, the bispecific antibodies according to the invention are generated as follows: (i) "Al" IL-18 antigen binding domain (duobody) paired with "Bl" IL-13 antigen binding domain(duobody); (ii) "A2" IL-18 antigen binding domain (CrossMab regular arm) paired with "B2" IL-13 antigen binding domain (CrossMab cross arm); (iii) "A3" IL-18 antigen binding domain (CrossMab cross arm) paired with "B3" IL-13 antigen binding domain (CrossMab regular arm); (iv) "A4" IL-18 antigen binding domain (WuxiBody regular arm) paired with "B4" IL-13 antigen binding domain (WuxiBody Wuxi arm); and (v) "A5" IL-18 antigen binding domain (WuxiBody Wuxi arm) paired with "B5" IL-13 antigen binding domain (WuxiBody regular arm).
[0010] The invention extends to both whole antibodies (i.e. immunoglobulins) with immunospecificity for IL-18 and IL-13, or functional fragments or variants thereof, as well as to antigen-binding fragments or regions of the corresponding full-length antibody.
[0011] The antibody or antigen-binding fragment thereof may be monovalent, divalent or polyvalent. Monovalent antibodies are dimers (HL) comprising a heavy (H) chain associated by a disulphide bridge with a light chain (L). Divalent antibodies are tetramer (H2L2) comprising two dimers associated by at least one disulphide bridge. Polyvalent antibodies may also be produced, for example by linking multiple dimers. The basic structure of an antibody molecule consists of two identical light chains and two identical heavy chains which associate non-covalently and can be linked by disulphide bonds. Each heavy and light chain contains an amino-terminal variable region of about 110 amino acids, and constant sequences in the remainder of the chain. The variable region includes several hypervariable regions, or Complementarity Determining Regions (CDRs), that form the antigen-binding site of the antibody molecule and determine its specificity for the antigen, i.e. IL-18 and IL-13 (e.g. an epitope). On either side of the CDRs of the heavy and light chains is a framework region, a relatively conserved sequence of amino acids that anchors and orients the CDRs. Antibody fragments may include a bi-specific antibody (BsAb) or a chimeric antigen receptor (CAR).
[0012] The heavy chain constant region typically comprises three domains, CHI, CH2, and CHS. Each light chain typically comprises a light chain variable region (VL) and a light chain constant region. The light chain constant region typically comprises one domain, abbreviated CL.
[0013] Each heavy chain and light chain generally comprise three CDRs and four FRs, arranged in the following order (from N-terminus to C-terminus): FR1 - CDR1 - FR2 -CDR2 - FR3 - CDR3 - FR4. The CDRs are involved in antigen binding and conferantigen specificity and binding affinity to the antibody. See Kabat et al., Sequences of Proteins of Immunological Interest 5th ed. (1991) Public Health Service, National Institutes of Health, Bethesda, MD, incorporated by reference in its entirety.
[0014] The heavy chain from any vertebrate species can be assigned to one of five different classes (or isotypes): IgA, IgD, IgE, IgG, and IgM. These classes are also designated a, 6, e, y, and p, respectively. The IgG and IgA classes are further divided into subclasses on the basis of differences in sequence and function. Humans express the following subclasses: IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2. In one embodiment, the antibody is of the IgG antibody class. In one embodiment, the antibody is of the IgGl antibody class.
[0015] The light chain from any vertebrate species can be assigned to one of two types, called kappa and lambda, based on the sequence of the constant domain.
[0016] The constant region consists of one of five heavy chain sequences (p, y,
[0017]
[0018] a, or e) and one of two light chain sequences (K or A). The heavy chain constant region sequences determine the isotype of the antibody and the effector functions of the molecule.
[0019] In some embodiments, the antibody or antigen-binding fragment thereof is isolated or purified.
[0020] In one embodiment, the antibody or antigen-binding fragment thereof comprises a polyclonal antibody, or an antigen-binding fragment thereof. The antibody or antigenbinding fragment thereof may be generated in a rabbit, mouse or rat.
[0021] In another embodiment, the antibody or antigen-binding fragment thereof comprises a monoclonal antibody or antigen-binding fragment thereof. In some embodiments, the antibody of the invention is a human antibody. As used herein, the term "human antibody" can mean an antibody, such as a monoclonal antibody, which comprises substantially the same heavy and light chain CDR amino acid sequences as found in a particular human antibody exhibiting immunospecificity for IL-18 or IL-13, or a variant or fragment thereof. An amino acid sequence, which is substantially the same as a heavy or light chain CDR, exhibits a considerable amount of sequence identity when compared to a reference sequence. Such identity is definitively known or recognizable as representing the amino acid sequence of the particular human antibody.
[0022] Substantially the same heavy and light chain CDR amino acid sequence can have, for example, minor modifications or conservative substitutions of amino acids. Such ahuman antibody maintains its function of selectively binding to IL-18 or IL-13, or a variant or fragment thereof.
[0023] The term "human monoclonal antibody" can include a monoclonal antibody with substantially or entirely human CDR amino acid sequences produced, for example by recombinant methods such as production by a phage library, by lymphocytes or by hybridoma cells.
[0024] The term "monoclonal antibody" refers to an antibody from a population of substantially homogeneous antibodies. A population of substantially homogeneous antibodies comprises antibodies that are substantially similar and that bind the same epitope(s), except for variants that may normally arise during production of the monoclonal antibody. Such variants are generally present in only minor amounts. A monoclonal antibody is typically obtained by a process that includes the selection of a single antibody from a plurality of antibodies. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, yeast clones, bacterial clones, or other recombinant DNA clones. The selected antibody can be further altered, for example, to improve affinity for the target (by so-called "affinity maturation"), to humanize the antibody, to improve its production in cell culture, and / or to reduce its immunogenicity in a subject.
[0025] The term "humanised antibody" can mean an antibody from a non-human species (e.g. mouse or rabbit) whose protein sequences have been modified to increase their similarity to antibodies produced naturally in humans.
[0026] The antibody may be a recombinant antibody. The term "recombinant human antibody" can include a human antibody produced using recombinant DNA technology.
[0027] The term "antigen-binding region" can mean a region of the antibody having specific binding affinity for its target antigen, for example, IL-18 and IL-13, or variants or fragments thereof. In some embodiments, the fragment is an epitope. The antigenbinding region may be a hypervariable CDR or a functional portion thereof. The term "functional portion" of a CDR can mean a sequence within the CDR which shows specific affinity for the target antigen. The functional portion of a CDR may comprise a ligand which specifically binds to IL-18 and IL-13, or variants or fragments thereof.The term "CDR" can mean a hypervariable region in the heavy and light variable chains. There may be one, two, three or more CDRs in each of the heavy and light chains of the antibody. Normally, there are at least three CDRs on each chain which, when configured together, form the antigen-binding site, i.e. the three-dimensional combining site with which the antigen binds or specifically reacts. It has however been postulated that there may be four CDRs in the heavy chains of some antibodies.
[0028] The definition of CDR also includes overlapping or subsets of amino acid residues when compared against each other. The exact residue numbers which encompass a particular CDR or a functional portion thereof will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid sequence of the antibody.
[0029] The amino acid sequence boundaries of a CDR can be determined by using any of a number of known numbering schemes, including those described by Kabat et al., supra ("Kabat" numbering scheme); Al-Lazikani et al., 1997, J. Mol. Biol., 273:927-948 ("Chothia" numbering scheme); MacCallum et al., 1996, J. Mol. Biol. 262:732-745 ("Contact" numbering scheme); Lefranc et al., Dev. Comp. Immunol., 2003, 27:55-77 ("IMGT" numbering scheme); and Honegge and Pluckthun, J. Mol. Biol., 2001, 309:657-70 ("AHo" numbering scheme).
[0030] The term "functional fragment" of an antibody can mean a portion of the antibody which retains a functional activity. A functional activity can be, for example antigen binding activity or specificity. A functional activity can also be, for example, an effector function provided by an antibody constant region. The term "functional fragment" is also intended to include, for example, fragments produced by protease digestion or reduction of a human monoclonal antibody and by recombinant DNA methods known to those skilled in the art. Human monoclonal antibody functional fragments include, for example individual heavy or light chains and fragments thereof, such as VL, VH and Fd; monovalent fragments, such as Fv, Fab, and Fab'; bivalent fragments such as F(ab')2; single chain Fv (scFv); bivalent or trivalent scFvs, scFv-Fc-scFv, an IgG-scFv, an IgG-dAb, KIH-IgG, KX-BODY, KIH-FC Fab / scFv, tri / tetraspecific, KIH tri / tetra-specific, or a tandem scFv, and Fc fragments. The Fc fragment of the antibody may be disabled by introducing amino acid substitutions into the Fc region, which silence or reduce the effector function of the antibody.
[0031] The term "VL fragment" can mean a fragment of the light chain of a humanmonoclonal antibody which includes all or part of the light chain variable region, including the CDRs. A VL fragment can further include light chain constant region sequences.
[0032] The term "VH fragment" can mean a fragment of the heavy chain of a human monoclonal antibody which includes all or part of the heavy chain variable region, including the CDRs.
[0033] The term "Fd fragment" can mean the heavy chain variable region coupled to the first heavy chain constant region, i.e. VH and CH-1. The "Fd fragment" does not include the light chain, or the second and third constant regions of the heavy chain.
[0034] The term "Fv fragment" can mean a monovalent antigen-binding fragment of a human monoclonal antibody, including all or part of the variable regions of the heavy and light chains, and absent of the constant regions of the heavy and light chains. The variable regions of the heavy and light chains include, for example, the CDRs. For example, an Fv fragment includes all or part of the amino terminal variable region of about 110 amino acids of both the heavy and light chains.
[0035] The term "Fab fragment" can mean a monovalent antigen-binding fragment of a human monoclonal antibody that is larger than an Fv fragment. For example, a Fab fragment includes the variable regions, and all or part of the first constant domain of the heavy and light chains. Thus, a Fab fragment additionally includes, for example, amino acid residues from about 110 to about 220 of the heavy and light chains.
[0036] The term "Fab' fragment" can mean a monovalent antigen-binding fragment of a human monoclonal antibody that is larger than a Fab fragment. For example, a Fab' fragment includes all of the light chain, all of the variable region of the heavy chain, and all or part of the first and second constant domains of the heavy chain. For example, a Fab' fragment can additionally include some or all of amino acid residues 220 to 330 of the heavy chain.
[0037] The term "F(ab')2 fragment" can mean a bivalent antigen-binding fragment of a human monoclonal antibody. An F(ab')2 fragment includes, for example, all or part of the variable regions of two heavy chains-and two light chains, and can further include all or part of the first constant domains of two heavy chains and two light chains.The term "single chain Fv (scFv)" can mean a fusion of the variable regions of the heavy (VH) and light chains (VL) connected with a short linker peptide.
[0038] One skilled in the art knows that the exact boundaries of a fragment of an antibody are not important, so long as the fragment maintains a functional activity. Using well-known recombinant methods, one skilled in the art can engineer a polynucleotide sequence to express a functional fragment with any endpoints desired for a particular application. A functional fragment of the antibody may comprise or consist of a fragment with substantially the same heavy and light chain variable regions as the human antibody.
[0039] Typically, the antigen-binding fragment thereof, with respect to the first aspect of the invention, are immunospecific for IL-18 or IL-13, or a functional fragment or variant thereof. The antigen-binding fragment thereof may comprise or consist of any of the fragments selected from a group consisting of VH, VL, Fd, Fv, Fab, Fab', scFv, F (ab')2 and Fc fragment.
[0040] The antigen-binding fragment thereof may be a single domain antibody (sdAb), otherwise referred to as a nanobody, which the skilled person would understand is an antibody fragment consisting of a single monomeric variable antibody domain.
[0041] The antigen-binding fragment thereof may comprise or consist of any one of the antigen binding region sequences of the VL, any one of the antigen binding region sequences of the VH, or a combination of VL and VH antigen binding regions of a human antibody. The appropriate number and combination of VH and VL antigen binding region sequences may be determined by those skilled in the art depending on the desired affinity and specificity and the intended use of the antigen-binding fragment. Functional fragments or antigen-binding fragments of antibodies may be readily produced and isolated using methods well known to those skilled in the art. Such methods include, for example, proteolytic methods, recombinant methods and chemical synthesis. Proteolytic methods for the isolation of functional fragments comprise using human antibodies as a starting material. Enzymes suitable for proteolysis of human immunoglobulins may include, for example, papain, and pepsin. The appropriate enzyme may be readily chosen by one skilled in the art, depending on, for example, whether monovalent or bivalent fragments are required. For example, papain cleavage results in two monovalent Fab' fragments that bind antigen and an Fc fragment. Pepsin cleavage, for example, results in a bivalent F (ab')fragment. An F (ab')2 fragment of the invention may be further reduced using, for example, DTT or 2-mercaptoethanol to produce two monovalent Fab' fragments.
[0042] Functional or antigen-binding fragments of antibodies produced by proteolysis may be purified by affinity and column chromatographic procedures. For example, undigested antibodies and Fc fragments may be removed by binding to protein A. Additionally, functional fragments may be purified by virtue of their charge and size, using, for example, ion exchange and gel filtration chromatography. Such methods are well known to those skilled in the art.
[0043] The antibody or antigen-binding fragment thereof may be produced by recombinant methodology. In some embodiments, one initially isolates a polynucleotide encoding desired regions of the antibody heavy and light chains. Such regions may include, for example, all or part of the variable region of the heavy and light chains. In some embodiments, such regions can particularly include the antigen binding regions of the heavy and light chains, typically the antigen binding sites, most typically the CDRs.
[0044] The polynucleotide encoding the bispecific antibody or antigen-binding fragment thereof according to the invention may be produced using methods known to those skilled in the art. The polynucleotide encoding the bispecific antibody or antigenbinding fragment thereof may be directly synthesized by methods of oligonucleotide synthesis known in the art. Alternatively, smaller fragments may be synthesized and joined to form a larger functional fragment using recombinant methods known in the art.
[0045] As used herein, the term "immunospecificity" can mean the binding region of the bispecific antibody or antigen-binding fragment thereof is capable of immunoreacting with IL-18 and IL-13, by specifically binding therewith. In some embodiments, the bispecific antibody or antigen-binding fragment thereof can selectively interact with an antigen (i.e. IL-18 and IL-13) with an affinity constant of approximately 10'5to 10'13M’1, or IO’6to IO’9M’1, or 10’10to IO’12M’1.
[0046] The term "immunoreact" can mean the binding region is capable of eliciting an immune response upon binding with IL-18 and IL-13, or an epitope thereof.
[0047] The term "epitope" can mean any region of an antigen with the ability to elicit, and combine with, a binding region of the bispecific antibody or antigen-binding fragment thereof. The epitope may be linear. This can mean that the antibody interacts with aplurality of continuous amino acids of the antigen, and so the epitope can consist of these defined amino acids. Alternatively, the epitope may be conformational, i.e. nonlinear or discontinuous. This can mean that the antibody interacts with multiple, distinct segments from the primary amino acid sequence of the antigen.
[0048] Thus, the bispecific antibody or antigen-binding fragment thereof may comprise a heavy chain. The heavy chain may be selected from the group consisting of IgA; IgD; IgE; IgG and IgM. In some embodiments, the heavy chain is an IgA. In some embodiments, the heavy chain is an IgG.
[0049] The heavy chain may be an IgGl. The heavy chain may be an IgG2. The heavy chain may be an IgG3. The heavy chain may be an IgG4. The heavy chain may be an IgAl. The heavy chain may be an IgA2.
[0050] In some embodiments, the bispecific antibody is a heterodimeric antibody. In some embodiments, the bispecific antibody is derived from two monoclonal antibodies (mAbs), an anti-IL-18 mAb or antigen-binding fragment thereof, and an anti-IL-13 mAb or antigen-binding fragment thereof. In some embodiments, the anti-IL-18 mAb or antigen-binding fragment thereof contributes to the first antigen-binding domain binding to IL-18 in the bispecific antibody. In some embodiments, the anti-IL-13 mAb or antigen-binding fragment thereof contributes to the second antigen-binding domain binding to IL-13 in the bispecific antibody. In some embodiments, each of these mAbs contributes one distinct heavy (H) chain and one distinct light (L) chain to the bispecific antibody, resulting in four chains in the bispecific antibody. In some embodiments, the four chains in the bispecific antibody are covalently linked via five inter-chain disulfide bonds.
[0051] In some embodiments, the bispecific antibody comprises: a) a first antigen-binding domain comprising a first light chain variable domain (VL1) and a first heavy chain variable domain (VH1), that binds specifically to IL-18 or a functional fragment or variant thereof, and b) a second antigen-binding domain comprising a second light chain variable domain (VL2) and a second heavy chain variable domain (VH2), that binds specifically to IL-13 or a functional fragment or variant thereof.
[0052] In some embodiments, the first antigen-binding domain comprises an IL-18 scFv or an IL-18 Fab. In some embodiments, the first antigen-binding domain comprises one or two IL-18 Fabs.In some embodiments, the second antigen-binding domain comprises an IL-13 scFv or an IL-13 Fab. In some embodiments, the second antigen-binding domain comprises one or two IL-13 Fabs.
[0053] In some embodiments, the first antigen-binding domain comprises an IL-18 scFv and the second antigen-binding domain comprises an IL-13 scFv. In some embodiments, the two scFv are linked to each other by a shorter linked peptide.
[0054] In some embodiments, the first and second antigen-binding domains of the bispecific antibody or antigen-binding fragment thereof are linked. In some embodiments, that linkage is a direct linkage, and the regions are fused to each other. In some embodiments, the first binding domain and / or the second binding domain are fused to a Fc polypeptide chain. In some embodiments, the second binding domain (e.g. IL-13 Fab) is linked, e.g., via a polypeptide linker, to the N-terminus of the first binding domain. In some embodiments, the second binding domain (e.g. IL-13 Fab) is linked, e.g., fused, to the N-terminus of the first binding domain.
[0055] Protocols for generating bispecific antibodies are known in the art; including but not limited to, for example, the "knob in a hole" approach; the electrostatic steering Fc pairing; Strand Exchange Engineered Domains (SEED) heterodimer formation; Fab arm exchange; double antibody conjugate, e.g., by antibody cross-linking to generate a bi-specific structure using a heterobifunctional reagent having an amine-reactive group and a sulfhydryl reactive group; bispecific antibody or antibody-like molecule determinants generated by recombining half antibodies (heavy-light chain pairs or Fabs) from different antibodies or antibody-like molecules through cycle of reduction and oxidation of disulfide bonds between the two heavy chains; trifunctional antibodies, e.g., three Fab' fragments cross-linked through sulfhydryl reactive groups; biosynthetic binding proteins, e.g., pair of scFvs cross-linked through C-terminal tails preferably through disulfide or amine-reactive chemical cross-linking; bifunctional antibodies, e.g., Fab fragments with different binding specificities dimerized through leucine zippers that have replaced the constant domain; bispecific and oligospecific mono-and oligovalent receptors, e.g., VH-CH1 regions of two antibodies (two Fab fragments) linked through a polypeptide spacer between the CHI region of one antibody and the VH region of the other antibody typically with associated light chains; bispecific DNA-antibody conjugates, e.g., crosslinking of antibodies or Fab fragments through a double stranded piece of DNA; bispecific fusion proteins, e.g., an expression construct containing two scFvs with a hydrophilic helical peptide linker between them and a full constant region; multivalent and multi-specific binding proteins, e.g., dimerof polypeptides having first domain with binding region of Ig heavy chain variable region, and second domain with binding region of Ig light chain variable region, generally termed diabodies (higher order structures are also encompassed creating for bispecific, trispecific, or tetraspecific molecules; minibody constructs with linked VL and VH chains further connected with peptide spacers to an antibody hinge region and CH3 region, which can be dimerized to form bispecific / multivalent molecules; VL and VH domains linked with a short peptide linker (e.g., 5 or 10 amino acids) or no linker at all in either orientation, which can form dimers to form bispecific diabodies; trimers and tetramers; string of VH domains (or VL domains in family members) connected by peptide linkages with crosslinkable groups at the C-terminus further associated with VL domains to form a series of Fvs (or scFvs); VL and VH domains, scFvs, or Fabs wherein one of the antigens is bound monovalently and one of the antigens is bound bivalently, optionally comprising heterodimeric Fc regions; and single chain binding polypeptides with both a VL and VH domain linked through a peptide linker are combined into multivalent structures through non-covalent or chemical crosslinking to form, e.g., homobivalent, heterobivalent, trivalent, and tetravalent structures using both scFv or diabody type format.
[0056] Controlled Fab-arm exchange (cFAE) is the in vitro post-production process in which IgGl half-molecules recombine with other IgGl half-molecules to generate bispecific IgGl antibodies. In particular, this involves the recombination of antigen-binding arms (heavy chain-light chain (H-L) pairs) between individually expressed antibody molecules. This unidirectional reaction takes place under tailored reaction conditions in vitro with IgGl antibodies containing single matched point-mutations in the CH3 domains. To promote Fc heterodimerization, one antibody is engineered with an F405L mutation and the other with a K409R mutation. The two parental antibodies are expressed separately, mixed at equimolar ratios, and subjected to mild reducing conditions to allow Fab-arm exchange. Upon removal of the reducing agent, interheavy chain disulfide bonds reform, stabilizing the heterodimeric bispecific antibody.
[0057] The DuoBody® biotechnology involves three basic steps to generate stable bispecific human IgGl antibodies. In a first step, two IgGls, each containing single matched mutations in the third constant (CH3) domain (lysine at position 409 to arginine, K409R; phenylalanine at position 405 to leucine, F405L), are produced separately using recombinant mammalian expression systems. These mutations allow the homodimeric, monospecific parental mAbs against different targets to recombine to form a single heterodimeric, bispecific antibody. Subsequently, these IgGl antibodies are purified according to standard processes for recovery and purification. Afterproduction and purification (post-production), the two antibodies are recombined using controlled Fab-arm exchange (cFAE), resulting in a bispecific antibody product.
[0058] The basis of the CrossMab technology is the crossover of antibody domains within one arm of a bispecific IgG antibody enabling correct chain association. This can be achieved by exchange of different domains within the Fab-fragment. Either the Fab domains (in the CrossMabFabformat), or only the variable VH-VL domains (CrossMabVH-VLformat) or the constant CH1-CL domains (CrossMabCH1'CLformat) within the Fab-fragment can be exchanged for this purpose. For example, the Fab arm retains a conventional heavy chain / light chain pairing, and the second arm contains variable domains which have been swapped at the molecular level to promote correct chain pairing. The Fc is engineered for heterodimerization with one arm using a 'knob' mutation (T366W) and 'hole' mutations (T366S, L368A, Y407V) on the other arm.
[0059] WuxiBody technology involves the replacement of one parental mAb's CH1 / CL region by the T cell receptor (TOR) constant domain. WuXiBody's design ensures cognate HC-LC pairing, the same goal as that being aimed by the CrossMab technology. One Fab arm comprises immunoglobulin (IgG) constant domains and the other Fab arm comprises engineered human TCR constant domains (Co / CP), enabling orthogonal heavy / light chain pairing. The Fc is engineered for heterodimerization with one arm using a 'knob' mutation (T366W) and 'hole' mutations (T366S, L368A, Y407V) on the other arm.
[0060] Mispairing and mismatching between light chains and heavy chains can occur when preparing the bispecific antibody or antigen binding fragment thereof. Mispairing refers to the incorrect pairing of heavy and light chains during antibody assembly. Mismatching refers to the presence of different types of antibody chains within a bispecific antibody, even if the chains are correctly paired. This can occur due to genetic or structural variability within the antibody chains, leading to a broader spectrum of antibody species. Antibodies with mispairing and / or mismatches may have to be separated from the desired bispecific antibodies by purification processes.
[0061] In one embodiment, the amino acid sequence of IL-18 may be provided herein as SEQ ID No: 42, as follows:
[0062] MAAEPVEDNCINFVAMKFIDNTLYFIAEDDENLESDYFGKLESKLSVIRNLNDQVLFIDQGNRPLFEDMTDSDCRDNAPRT IFI ISMYKDSQPRGMAVTI SVKCEKISTLSCENKI ISFKEMNPPDNIKDTKSDI IFFQRSVPGHDNKMQFESSSYEGYFLA CEKERDLFKLI LKKEDELGDRS IMFTVQNED
[0063] [SEQ ID No: 42]Thus, in one embodiment, the bispecific antibody or antigen-binding fragment thereof binds to one or more amino acids within a sequence comprising or consisting of a sequence as substantially set out in SEQ ID No: 42, or a functional fragment or variant thereof.
[0064] In one embodiment, the amino acid sequence of IL-13 may be provided herein as SEQ ID No: 43, as follows:
[0065] MHPLLNPLLLALGLMALLLTTVIALTCLGGFASPGPVPPSTALRELIEELVNITQNQKAPLCNGSMVWSINLTAGMYCAAL ESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVKDLLLHLKKLFREGQFN
[0066] [SEQ ID No: 43]
[0067] Thus, in one embodiment, the bispecific antibody or antigen-binding fragment thereof binds to one or more amino acids within a sequence comprising or consisting of a sequence as substantially set out in SEQ ID No: 43, or a functional fragment or variant thereof.
[0068] It will be appreciated that "functional fragment or variant thereof" refers to fragments and variants of IL-18 and / or IL-13 that retain at least part of the activity of IL-18 and / or IL-13.
[0069] As described in the Examples, the inventors have surprisingly demonstrated that the bispecific antibodies or antigen-binding fragments referred to herein, are able to significantly target IL-18 and IL-13, or functional fragments or variants thereof, and each of these antibodies are defined below in detail. The CDR, VH, VL, CH and CL sequences of these antibodies are conveniently summarised in the table shown in Figure 12. The sequences are provided using Kabat, Chothia, IMGT and Combined numbering schemes.
[0070] Al-Bl (IL-18 / IL-13 Duobodv) ("WBP30404 7")
[0071] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as Al-Bl.
[0072] First antigen-binding domain (IL-18)
[0073] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 1, 4 or 6, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 2, 5 or 7, or a variant or fragment thereof.
[0074] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 3 or 8, or a variant or fragment thereof.
[0075] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8.
[0076] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 8.
[0077] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 14, or a variant or fragment thereof.
[0078] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 9 or 12, or a variant or fragment thereof.
[0079] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 10 or 13, or a variant or fragment thereof.
[0080] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 11, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0081] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0082] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 15, or a variant or fragment thereof.
[0083] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0084] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0085] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0086] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consistingof SEQ ID No: 5, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0087] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0088] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15.
[0089] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 17, or a variant or fragment thereof.
[0090] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.
[0091] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 17 and a light chain constant region comprising or consisting of SEQ ID No: 21.
[0092] Second antigen-binding domain (IL-13)
[0093] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 24, 27 29 or 32, or a variant or fragment thereof.
[0094] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 25, 28 or 30, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 26 or 31, or a variant or fragment thereof.
[0095] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31.
[0096] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31.
[0097] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 38, or a variant or fragment thereof.
[0098] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 33 or 36, or a variant or fragment thereof.
[0099] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 34 or 37, or a variant or fragment thereof.
[0100] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 35, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0101] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0102] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 39, or a variant or fragment thereof.
[0103] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0104] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0105] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0106] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, aCDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0107] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0108] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0109] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.
[0110] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 41, or a variant or fragment thereof.
[0111] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.
[0112] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 41 and a light chain constant region comprising or consisting of SEQ ID No: 21.
[0113] A2-B2 (IL-18 CrossMab Regular Arm / IL-13 CrossMab Cross Arm)
[0114] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as A2-B2.First antigen-binding domain (IL-18)
[0115] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 1, 4 or 6, or a variant or fragment thereof.
[0116] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 2, 5 or 7, or a variant or fragment thereof.
[0117] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 3 or 8, or a variant or fragment thereof.
[0118] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8.
[0119] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 8.
[0120] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 14, or a variant or fragment thereof.
[0121] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 9 or 12, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 10 or 13, or a variant or fragment thereof.
[0122] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 11, or a variant or fragment thereof.
[0123] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0124] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0125] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 15, or a variant or fragment thereof.
[0126] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0127] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0128] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consistingof SEQ ID No: 2, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0129] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0130] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0131] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15.
[0132] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 18, or a variant or fragment thereof.
[0133] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.
[0134] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 18 and a light chain constant region comprising or consisting of SEQ ID No: 21.
[0135] Second antigen-binding domain (IL- 13)In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 33 or 36, or a variant or fragment thereof.
[0136] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 34 or 37, or a variant or fragment thereof.
[0137] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 35, or a variant or fragment thereof.
[0138] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-H2 domain comprising or consisting of SEQ ID No: 34 or 37 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 35.
[0139] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33, a CDR-H2 domain comprising or consisting of SEQ ID No: 34 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 35. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 36, a CDR-H2 domain comprising or consisting of SEQ ID No: 37 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 35.
[0140] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 39, or a variant or fragment thereof.
[0141] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 24, 27 , 29 or 32, or a variant or fragment thereof.
[0142] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 25, 28 or 30, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 26 or 31, or a variant or fragment thereof.
[0143] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 26 or 31.
[0144] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 24, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 27 , a CDR-L2 domain comprising or consisting of SEQ ID No: 28, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 29, a CDR-L2 domain comprising or consisting of SEQ ID No: 30, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 31. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 31.
[0145] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 38, or a variant or fragment thereof.
[0146] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0147] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-H2 domain comprising or consisting of SEQ ID No: 34 or 37, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 24, 27, 29 or 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, and a CDR-L3 domain comprising or consisting of SEQ ID No: 26 or 31.In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33, a CDR-H2 domain comprising or consisting of SEQ ID No: 34, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 24, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, and a CDR-L3 domain comprising or consisting of SEQ ID No: 26.
[0148] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33, a CDR-H2 domain comprising or consisting of SEQ ID No: 34, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 27 , a CDR-L2 domain comprising or consisting of SEQ ID No: 28, and a CDR-L3 domain comprising or consisting of SEQ ID No: 26.
[0149] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 36, a CDR-H2 domain comprising or consisting of SEQ ID No: 37, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 29, a CDR-L2 domain comprising or consisting of SEQ ID No: 30, and a CDR-L3 domain comprising or consisting of SEQ ID No: 31.
[0150] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33, a CDR-H2 domain comprising or consisting of SEQ ID No: 34, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consisting of SEQ ID No: 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, and a CDR-L3 domain comprising or consisting of SEQ ID No: 31.
[0151] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 39, and a light chain variable region comprising or consisting of SEQ ID No: 38.
[0152] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 19, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 22, or a variant or fragment thereof.
[0153] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 19 and a light chain constant region comprising or consisting of SEQ ID No: 22.
[0154] A3-B3 (IL-18 CrossMab Cross Arm / IL-13 CrossMab Regular Arm)
[0155] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as A3-B3.
[0156] First antigen-binding domain (IL-18)
[0157] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 9 or 12, or a variant or fragment thereof.
[0158] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 10 or 13, or a variant or fragment thereof.
[0159] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 11, or a variant or fragment thereof.
[0160] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-H2 domain comprising or consisting of SEQ ID No: 10 or 13 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 11.
[0161] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9, a CDR-H2 domain comprising or consisting of SEQ ID No: 10 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 11. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 12, a CDR-H2 domain comprising or consisting of SEQ ID No: 13 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 11.In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 15, or a variant or fragment thereof.
[0162] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 1, 4 or 6, or a variant or fragment thereof.
[0163] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 2, 5 or 7, or a variant or fragment thereof.
[0164] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 3 or 8, or a variant or fragment thereof.
[0165] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-L2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 3 or 8.
[0166] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 1, a CDR-L2 domain comprising or consisting of SEQ ID No: 2, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 4, a CDR-L2 domain comprising or consisting of SEQ ID No: 5, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 6, a CDR-L2 domain comprising or consisting of SEQ ID No: 7, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 8.
[0167] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 14, or a variant or fragment thereof.
[0168] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-H2 domain comprising or consisting of SEQ ID No: 10 or 13, a CDR-H3 domain comprising or consisting of SEQ ID No: 11, a CDR-L1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-L2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, and a CDR-L3 domain comprising or consisting of SEQ ID No: 3 or 8.
[0169] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9, a CDR-H2 domain comprising or consisting of SEQ ID No: 10, a CDR-H3 domain comprising or consisting of SEQ ID No: 11, a CDR-L1 domain comprising or consisting of SEQ ID No: 1, a CDR-L2 domain comprising or consisting of SEQ ID No: 2, and a CDR-L3 domain comprising or consisting of SEQ ID No: 3.
[0170] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9, a CDR-H2 domain comprising or consisting of SEQ ID No: 10, a CDR-H3 domain comprising or consisting of SEQ ID No: 11, a CDR-L1 domain comprising or consisting of SEQ ID No: 4, a CDR-L2 domain comprising or consisting of SEQ ID No: 5, and a CDR-L3 domain comprising or consisting of SEQ ID No: 3.
[0171] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 12, a CDR-H2 domain comprising or consisting of SEQ ID No: 13, a CDR-H3 domain comprising or consisting of SEQ ID No: 11, a CDR-L1 domain comprising or consisting of SEQ ID No: 6, a CDR-L2 domain comprising or consisting of SEQ ID No: 7, and a CDR-L3 domain comprising or consisting of SEQ ID No: 8.
[0172] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 15, and a light chain variable region comprising or consisting of SEQ ID No: 14.
[0173] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 19, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 22, or a variant or fragment thereof.
[0174] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 19 and a light chain constant region comprising or consisting of SEQ ID No: 22.
[0175] Second antigen-binding domain (IL-13)
[0176] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 24, 7 , 29 or 32, or a variant or fragment thereof.
[0177] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 25, 28 or 30, or a variant or fragment thereof.
[0178] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 26 or 31, or a variant or fragment thereof.
[0179] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31.
[0180] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 7 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31.In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 38, or a variant or fragment thereof.
[0181] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 33 or 36, or a variant or fragment thereof.
[0182] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 34 or 37, or a variant or fragment thereof.
[0183] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 35, or a variant or fragment thereof.
[0184] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0185] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0186] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 39, or a variant or fragment thereof.
[0187] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0188] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0189] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0190] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0191] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0192] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 18, or a variant or fragment thereof.
[0193] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.
[0194] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 18 and a light chain constant region comprising or consisting of SEQ ID No: 21.
[0195] A4-B4 (IL-18 WuxiBodv Regular Arm / IL-13 WuxiBodv Wuxi Arm)
[0196] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as A4-B4.
[0197] First antigen-binding domain (IL-18)
[0198] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 1, 4 or 6, or a variant or fragment thereof.
[0199] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 2, 5 or 7, or a variant or fragment thereof.
[0200] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 3 or 8, or a variant or fragment thereof.
[0201] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8.
[0202] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3.In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 8.
[0203] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 14, or a variant or fragment thereof.
[0204] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 9 or 12, or a variant or fragment thereof.
[0205] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 10 or 13, or a variant or fragment thereof.
[0206] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 11, or a variant or fragment thereof.
[0207] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0208] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 15, or a variant or fragment thereof.
[0209] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0210] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0211] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0212] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0213] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15.
[0214] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 18, or a variant or fragment thereof.
[0215] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.
[0216] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 18 and a light chain constant region comprising or consisting of SEQ ID No: 21.
[0217] Second antigen-binding domain (IL-13)
[0218] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 24, 7 , 29 or 32, or a variant or fragment thereof.
[0219] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 25, 28 or 30, or a variant or fragment thereof.
[0220] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 26 or 31, or a variant or fragment thereof.
[0221] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31.
[0222] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domaincomprising or consisting of SEQ ID No: 27, a CDR-H2 domain comprising or consisting of SEQ ID No: 28 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31.
[0223] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 40, or a variant or fragment thereof.
[0224] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 33 or 36, or a variant or fragment thereof.
[0225] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 34 or 37, or a variant or fragment thereof.
[0226] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 35, or a variant or fragment thereof.
[0227] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0228] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35. In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 39, or a variant or fragment thereof.
[0229] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0230] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0231] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0232] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0233] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0234] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consistingof SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0235] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 40, and a light chain variable region comprising or consisting of SEQ ID No: 39.
[0236] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 20, or a variant or fragment thereof.
[0237] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 23, or a variant or fragment thereof.
[0238] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 20 and a light chain constant region comprising or consisting of SEQ ID No: 23.
[0239] A5-B5 (IL-18 WuxiBodv Wuxi Arm / IL-13 WuxiBodv Regular Arm)
[0240] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as A5-B5.
[0241] First antigen-binding domain (IL-18)
[0242] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 1, 4 or 6, or a variant or fragment thereof.
[0243] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 2, 5 or 7, or a variant or fragment thereof.
[0244] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 3 or 8, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8.
[0245] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 3. In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 8.
[0246] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 16, or a variant or fragment thereof.
[0247] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 9 or 12, or a variant or fragment thereof.
[0248] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 10 or 13, or a variant or fragment thereof.
[0249] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 11, or a variant or fragment thereof.
[0250] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0251] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consistingof SEQ ID No: 10, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11. In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0252] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 15, or a variant or fragment thereof.
[0253] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0254] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0255] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0256] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 4, a CDR-H2 domain comprising or consisting of SEQ ID No: 5, a CDR-H3 domain comprising or consisting of SEQ ID No: 3, a CDR-L1 domain comprising or consisting of SEQ ID No: 9, a CDR-L2 domain comprising or consisting of SEQ ID No: 10, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0257] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 8, a CDR-LI domain comprising or consisting of SEQ ID No: 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11.
[0258] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 16, and a light chain variable region comprising or consisting of SEQ ID No: 15.
[0259] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 20, or a variant or fragment thereof.
[0260] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 23, or a variant or fragment thereof.
[0261] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 20 and a light chain constant region comprising or consisting of SEQ ID No: 23.
[0262] Second antigen-binding domain (IL-13)
[0263] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 24, 7 , 29 or 32, or a variant or fragment thereof.
[0264] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 25, 28 or 30, or a variant or fragment thereof.
[0265] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 26 or 31, or a variant or fragment thereof.
[0266] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31.In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 26. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31. In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 31.
[0267] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 38, or a variant or fragment thereof.
[0268] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 33 or 36, or a variant or fragment thereof.
[0269] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 34 or 37, or a variant or fragment thereof.
[0270] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 35, or a variant or fragment thereof.
[0271] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0272] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35. In one embodiment, the second antigen-binding domain comprises a CDR-L1domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 37, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0273] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 39, or a variant or fragment thereof.
[0274] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0275] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0276] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0277] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 27 , a CDR-H2 domain comprising or consisting of SEQ ID No: 28, a CDR-H3 domain comprising or consisting of SEQ ID No: 26, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0278] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 29, a CDR-H2 domain comprising or consisting of SEQ ID No: 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 36, a CDR-L2 domaincomprising or consisting of SEQ ID No: 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0279] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, a CDR-H3 domain comprising or consisting of SEQ ID No: 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33, a CDR-L2 domain comprising or consisting of SEQ ID No: 34, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
[0280] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.
[0281] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 18, or a variant or fragment thereof.
[0282] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 21, or a variant or fragment thereof.
[0283] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 18 and a light chain constant region comprising or consisting of SEQ ID No: 21.
[0284] In one embodiment, the disclosure provides a bispecific antibody or antigen-binding fragment thereof, comprising first and second antigen-binding domains consisting of heavy chain variable regions comprising CDR1, CDR2, and CDR3 sequences and light chain variable regions comprising CDR1, CDR2, and CDR3 sequences, wherein: the heavy chain variable regions CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 1, 4, 6, 9, 12, 24, 27, 29, 32, 33 and 36, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the heavy chain variable regions CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 2, 5, 7, 10, 13, 25, 28, 30, 34 and 37, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the heavy chain variable regions CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 3, 8, 11, 26, 31and 35, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 9, 12, 1, 4, 6, 33, 36, 24, 27 , 29 and 32, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 10, 13, 2, 5, 7, 34, 37, 25, 28 and 30, or variant sequences thereof comprising 1 , 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions of CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 11, 3, 8, 35, 26 and 31, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof.
[0285] In one embodiment, the disclosure provides a bispecific antibody or antigen-binding fragment thereof, comprising first and second antigen-binding domains comprising heavy chain variable regions and light chain variable regions, wherein: the heavy chain variable regions comprise an amino acid sequence that is at least 80%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 15, 16, 38, 39 and 40; the light chain variable regions comprise an amino acid sequence that is at least 80%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 15, 14, 39 and 38. Alternatively the bispecific antibody or antigen-binding fragment thereof comprises first and second antigen-binding domains comprising heavy chain variable regions and light chain variable regions, wherein: the heavy chain variable regions comprise no more than 5 amino acid, or no more than 4 amino acid, or no more than 3 amino acid, or no more than 2 or no more than 1 amino acid change compared to the amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 15, 16, 38, 39 and 40; the light chain variable regions comprise no more than 5 amino acid, or no more than 4 amino acid, or no more than 3 amino acid, or no more than 2 or no more than 1 amino acid change compared to the amino acid sequence selected from the group consisting of SEQ ID NOs: 15, 14, 39 and 38. In this context, the term "change" refers to insertions, deletions and / or substitutions.
[0286] The antibody of the invention may comprise or consist of any sequence as defined in Figure 12.
[0287] Affinity matured variantsAs described in the Examples, the inventors have subjected a parent IL-18 antibody and a parent IL-13 antibody to affinity maturation in order to produce novel variants or mutants, with improved activity. The six CDR, VH, VL, CH and CL sequences of the affinity matured antibodies are summarised in the tables shown in Figure 14 (IL-18 affinity matured variants) and Figure 15 (IL-13 affinity matured variants).
[0288] Accordingly, in some embodiments, the first antigen-binding domain comprises any sequence as defined in Figure 14, and the second antigen-binding domain comprises any sequence as defined in Figure 15. For example, it will be appreciated that the IL-18 arm ("IL-18 mAbl", or "IL-18 mAb2", etc.) shown in Figure 14, may be combined with any of the IL-13 arms shown in Figure 15, such as "IL-13 mAb2" or "IL-13 mAb3", etc.
[0289] In some embodiments, the first antigen-binding domain comprises any of the heavy and light chain CDR sequences as defined in Figure 14. In some embodiments, the first antigen-binding domain comprises any of the heavy and light chain variable sequences as defined in Figure 14. In some embodiments, the first antigen-binding domain comprises any of the heavy and light chain constant sequences as defined in Figure 14.
[0290] In some embodiments, the second antigen-binding domain comprises any of the heavy and light chain CDR sequences as defined in Figure 15. In some embodiments, the second antigen-binding domain comprises any of the heavy and light chain variable sequences as defined in Figure 15. In some embodiments, the second antigen-binding domain comprises any of the heavy and light chain constant sequences as defined in Figure 15.
[0291] Figure 16 is a table showing the six CDR, VH, VL, CH and CL sequences of the first (IL-18) and second (IL-13) antigen-binding domains of the bispecific antibodies according to the invention. Accordingly, in some embodiments, the first and second antigenbinding domains comprise any of the heavy and light chain CDR sequences, any of the heavy and light chain variable sequences, and / or any of the heavy and light chain constant sequences, as defined in Figure 16.
[0292] BSAB 1
[0293] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as BSAB_1. It will be appreciated that this antibody is an anti-IL-18xIL-13 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3shown in Figure 13, with the FES YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S and / or M252Y, S254T, and T256E.
[0294] First antigen-binding domain (IL-18)
[0295] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 58, or a variant or fragment thereof.
[0296] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0297] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0298] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0299] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 59, or a variant or fragment thereof.
[0300] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0301] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0302] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0303] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0304] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0305] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0306] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 59, and a light chain variable region comprising or consisting of SEQ ID No: 47.
[0307] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 135, or a variant or fragment thereof.
[0308] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 136, or a variant or fragment thereof.
[0309] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 135 and a light chain constant region comprising or consisting of SEQ ID No: 136.
[0310] Second antigen-binding domain (IL- 13)In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0311] In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0312] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0313] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0314] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0315] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0316] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0317] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0318] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.
[0319] In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0320] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0321] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0322] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 137, or a variant or fragment thereof.
[0323] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0324] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 137 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0325] BSAB 4
[0326] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as BSAB_4. It will be appreciated that this antibody is an anti-IL-18xIL-13 CrossMab VH-VL anti-IL-13 cross, with knob on cross arm (orientation 1 shown in Figure 13, with the FES YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragmentcomprising the amino acid substitutions L234F, L235E and P331S and / or M252Y, S254T, and T256E.
[0327] First antigen-binding domain (IL-18)
[0328] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0329] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0330] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0331] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.
[0332] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0333] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 58, or a variant or fragment thereof.
[0334] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0335] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0336] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 58, a CDR-L2 domain comprising or consistingof SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0337] In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 59, or a variant or fragment thereof.
[0338] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0339] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 58, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0340] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 59.
[0341] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 137, or a variant or fragment thereof.
[0342] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0343] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 137 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0344] Second antigen-binding domain (IL-13)
[0345] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0346] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0347] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 120 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 121.
[0348] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.
[0349] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0350] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0351] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0352] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 116.
[0353] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0354] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 120, a CDR-H3 domain comprising or consisting of SEQ ID No: 121, a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and a CDR-L3 domain comprising or consisting of SEQ ID No: 116.
[0355] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 122, and a light chain variable region comprising or consisting of SEQ ID No: 117.
[0356] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 135, or a variant or fragment thereof.
[0357] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 136, or a variant or fragment thereof.
[0358] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 135 and a light chain constant region comprising or consisting of SEQ ID No: 136.
[0359] BSAB 5
[0360] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as BSAB_5. It will be appreciated that this antibody is an anti-IL-18xIL-13 CrossMab VH-VL anti-IL-13 cross, with hole on cross arm (orientation 2 shown in Figure 13, with the FES YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S and / or M252Y, S254T, and T256E.
[0361] First antigen-binding domain (IL-18)In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0362] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0363] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0364] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.
[0365] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0366] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 58, or a variant or fragment thereof.
[0367] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0368] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0369] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 58, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 59, or a variant or fragment thereof.
[0370] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0371] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 58, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0372] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 59.
[0373] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 139, or a variant or fragment thereof.
[0374] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0375] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 139 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0376] Second antigen-binding domain (IL-13)
[0377] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0378] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0379] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 120 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 121.
[0380] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.
[0381] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.
[0382] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0383] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0384] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 116.
[0385] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0386] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 120, a CDR-H3 domain comprising or consisting of SEQ ID No: 121, a CDR-L1 domain comprising or consisting of SEQ ID No: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and a CDR-L3 domain comprising or consisting of SEQ ID No: 116.
[0387] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 122, and a light chain variable region comprising or consisting of SEQ ID No: 117.
[0388] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 138, or a variant or fragment thereof.
[0389] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 136, or a variant or fragment thereof.
[0390] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 138 and a light chain constant region comprising or consisting of SEQ ID No: 136.
[0391] BSAB 6
[0392] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as BSAB_6. It will be appreciated that this antibody is an anti-IL-18xIL-13 CrossMab VH-VL anti-IL-18 cross, with hole on cross arm (orientation 4 shown in Figure 13, with the FES YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S and / or M252Y, S254T, and T256E.
[0393] First antigen-binding domain (IL-18)In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 58, or a variant or fragment thereof.
[0394] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0395] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0396] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0397] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 59, or a variant or fragment thereof.
[0398] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0399] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0400] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0401] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0402] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0403] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0404] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 59, and a light chain variable region comprising or consisting of SEQ ID No: 47.
[0405] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 138, or a variant or fragment thereof.
[0406] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 136, or a variant or fragment thereof.
[0407] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 138 and a light chain constant region comprising or consisting of SEQ ID No: 136.
[0408] Second antigen-binding domain (IL-13)
[0409] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0410] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0411] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0412] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0413] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0414] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0415] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0416] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0417] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0418] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0419] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0420] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 139, or a variant or fragment thereof.
[0421] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0422] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 139 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0423] BSAB 2
[0424] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as BSAB_2. It will be appreciated that this antibody is an anti-IL-18xIL-13 CrossMab CH1-CHL anti-IL-13 cross, with knob on cross arm (orientation 5 shown in Figure 13, with the FES YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S and / or M252Y, S254T, and T256E.
[0425] First antigen-binding domain (IL-18)In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0426] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0427] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0428] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.
[0429] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0430] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 58, or a variant or fragment thereof.
[0431] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0432] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0433] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 58, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 59, or a variant or fragment thereof.
[0434] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0435] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 58, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0436] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 59.
[0437] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 137, or a variant or fragment thereof.
[0438] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0439] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 137 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0440] Second antigen-binding domain (IL-13)
[0441] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0442] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0443] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0444] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0445] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0446] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0447] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0448] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0449] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0450] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0451] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0452] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 140, or a variant or fragment thereof.
[0453] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 141, or a variant or fragment thereof.
[0454] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 140 and a light chain constant region comprising or consisting of SEQ ID No: 141.
[0455] BSAB 7
[0456] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as BSAB_7. It will be appreciated that this antibody is an anti-IL-18xIL-13 CrossMab CH-CL anti-IL-13 cross, with hole on cross arm (orientation 6 shown in Figure 13, with the FES YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S and / or M252Y, S254T, and T256E.
[0457] First antigen-binding domain (IL-18)In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0458] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0459] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0460] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.
[0461] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0462] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 58, or a variant or fragment thereof.
[0463] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0464] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0465] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 58, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 59, or a variant or fragment thereof.
[0466] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0467] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 58, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0468] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 59.
[0469] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 143, or a variant or fragment thereof.
[0470] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0471] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 143 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0472] Second antigen-binding domain (IL-18)
[0473] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0474] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0475] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0476] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0477] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0478] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0479] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0480] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0481] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0482] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0483] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0484] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 142, or a variant or fragment thereof.
[0485] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 141, or a variant or fragment thereof.
[0486] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 142 and a light chain constant region comprising or consisting of SEQ ID No: 141.
[0487] BSAB 3
[0488] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as BSAB_3. It will be appreciated that this antibody is an anti-IL-18xIL-13 CrossMab CH1-CHL anti-IL-18 cross, with knob on cross arm (orientation 7 shown in Figure 13, with the FES YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S and / or M252Y, S254T, and T256E.
[0489] First antigen-binding domain (IL-18)In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0490] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0491] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0492] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.
[0493] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0494] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 58, or a variant or fragment thereof.
[0495] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0496] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0497] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 58, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 59, or a variant or fragment thereof.
[0498] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0499] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 58, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0500] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 59.
[0501] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 140, or a variant or fragment thereof.
[0502] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 141, or a variant or fragment thereof.
[0503] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 140 and a light chain constant region comprising or consisting of SEQ ID No: 141.
[0504] Second antigen-binding domain (IL-13)
[0505] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0506] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0507] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0508] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0509] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0510] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0511] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0512] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0513] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0514] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0515] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0516] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 137, or a variant or fragment thereof.
[0517] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0518] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 137 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0519] BSAB 8
[0520] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as BSAB_8. It will be appreciated that this antibody is an anti-IL-18xIL-13 CrossMab CH-CL anti-IL-18 cross, with hole on cross arm (orientation 8 shown in Figure 13, with the FES YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S and / or M252Y, S254T, and T256E.
[0521] First antigen-binding domain (IL-18)In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0522] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0523] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0524] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 46.
[0525] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0526] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 58, or a variant or fragment thereof.
[0527] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0528] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0529] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 58, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 51.In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 59, or a variant or fragment thereof.
[0530] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0531] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 58, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51.
[0532] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 59.
[0533] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 142, or a variant or fragment thereof.
[0534] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 141, or a variant or fragment thereof.
[0535] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 142 and a light chain constant region comprising or consisting of SEQ ID No: 141.
[0536] Second antigen-binding domain (IL-13)
[0537] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0538] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0539] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0540] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0541] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0542] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0543] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0544] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0545] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0546] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0547] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0548] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 139, or a variant or fragment thereof.
[0549] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0550] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 139 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0551] BSAB 9
[0552] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as BSAB_9. It will be appreciated that this antibody is an anti-IL-18xIL-13 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the LALA YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234A and L235A and / or M252Y, S254T, and T256E.
[0553] First antigen-binding domain (IL-18)In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 58, or a variant or fragment thereof.
[0554] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0555] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0556] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0557] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 59, or a variant or fragment thereof.
[0558] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0559] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0560] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0561] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0562] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0563] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0564] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 59, and a light chain variable region comprising or consisting of SEQ ID No: 47.
[0565] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 145, or a variant or fragment thereof.
[0566] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 136, or a variant or fragment thereof.
[0567] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 145 and a light chain constant region comprising or consisting of SEQ ID No: 136.
[0568] Second antigen-binding domain (IL-13)
[0569] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0570] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0571] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0572] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0573] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0574] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0575] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0576] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0577] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0578] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0579] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0580] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 144, or a variant or fragment thereof.
[0581] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0582] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 144 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0583] BSAB 10
[0584] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as BSAB_10. It will be appreciated that this antibody is an anti-IL-18xIL-13 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the LALA LS mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234A and L235A and / or M428L and N434S.
[0585] First antigen-binding domain (IL-18)In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 58, or a variant or fragment thereof.
[0586] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0587] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0588] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0589] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 59, or a variant or fragment thereof.
[0590] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0591] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0592] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0593] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0594] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0595] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0596] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 59, and a light chain variable region comprising or consisting of SEQ ID No: 47.
[0597] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 147, or a variant or fragment thereof.
[0598] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 136, or a variant or fragment thereof.
[0599] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 147 and a light chain constant region comprising or consisting of SEQ ID No: 136.
[0600] Second antigen-binding domain (IL-13)
[0601] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0602] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0603] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0604] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0605] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0606] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0607] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0608] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0609] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0610] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0611] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0612] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 146, or a variant or fragment thereof.
[0613] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0614] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 146 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0615] BSAB 11
[0616] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as BSAB_11. It will be appreciated that this antibody is an anti-IL-18xIL-13 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm FES LS (orientation 3 shown in Figure 13, with the FES LS mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S and / or M428L and N434S.
[0617] First antigen-binding domain (IL-18)In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 58, or a variant or fragment thereof.
[0618] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0619] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0620] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0621] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 59, or a variant or fragment thereof.
[0622] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0623] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0624] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0625] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0626] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0627] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0628] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 59, and a light chain variable region comprising or consisting of SEQ ID No: 47.
[0629] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 149, or a variant or fragment thereof.
[0630] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 136, or a variant or fragment thereof.
[0631] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 149 and a light chain constant region comprising or consisting of SEQ ID No: 136.
[0632] Second antigen-binding domain (IL-13)
[0633] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0634] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0635] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0636] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0637] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0638] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0639] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0640] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0641] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0642] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0643] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0644] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 148, or a variant or fragment thereof.
[0645] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0646] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 148 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0647] BSAB 12
[0648] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as BSAB_12. It will be appreciated that this antibody is an anti-IL-18xIL-13 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm orientation 3 shown in Figure 13, with the LAGA LS mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L235A and G237A and / or M428L and N434S.
[0649] First antigen-binding domain (IL-18)In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 58, or a variant or fragment thereof.
[0650] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0651] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0652] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0653] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 59, or a variant or fragment thereof.
[0654] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0655] In one embodiment, the v antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0656] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0657] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0658] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0659] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0660] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 59, and a light chain variable region comprising or consisting of SEQ ID No: 47.
[0661] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 151, or a variant or fragment thereof.
[0662] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 136, or a variant or fragment thereof.
[0663] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 151 and a light chain constant region comprising or consisting of SEQ ID No: 136.
[0664] Second antigen-binding domain (IL-13)
[0665] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0666] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0667] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0668] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0669] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0670] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0671] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0672] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0673] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0674] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0675] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0676] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 150, or a variant or fragment thereof.
[0677] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0678] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 150 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0679] BSAB 13
[0680] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as BSAB_13. It will be appreciated that this antibody is an anti-IL-18xIL-13 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the LAGA YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L235A and G237A and / or M252Y, S254T, and T256E.
[0681] First antigen-binding domain (IL-18)In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 58, or a variant or fragment thereof.
[0682] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0683] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0684] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0685] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 59, or a variant or fragment thereof.
[0686] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0687] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0688] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 46, or a variant or fragment thereof.
[0689] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0690] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0691] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0692] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 59, and a light chain variable region comprising or consisting of SEQ ID No: 47.
[0693] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 153, or a variant or fragment thereof.
[0694] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 136, or a variant or fragment thereof.
[0695] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 153 and a light chain constant region comprising or consisting of SEQ ID No: 136.
[0696] Second antigen-binding domain (IL-13)
[0697] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0698] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0699] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0700] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0701] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0702] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0703] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0704] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0705] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0706] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0707] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0708] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 152, or a variant or fragment thereof.
[0709] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0710] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 152 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0711] BSAB 14
[0712] In one embodiment, the bispecific antibody or antigen-binding fragment thereof is referred to herein as BSAB_14. It will be appreciated that this antibody is an anti-IL-18xIL-13 CrossMab VH-VL anti-IL-18 cross, with knob on cross arm (orientation 3 shown in Figure 13, with the FES YTE mutations). Accordingly, in some embodiments, the bispecific antibody or antigen-binding fragment thereof comprises an Fc fragment comprising the amino acid substitutions L234F, L235E and P331S and / or M252Y, S254T, and T256E.
[0713] First antigen-binding domain (IL-18)In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 58, or a variant or fragment thereof.
[0714] In one embodiment, the first antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 50, or a variant or fragment thereof.
[0715] In one embodiment, the first antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 51, or a variant or fragment thereof.
[0716] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 51.
[0717] In one embodiment, the first antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 59, or a variant or fragment thereof.
[0718] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 44, or a variant or fragment thereof.
[0719] In one embodiment, the first antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0720] In one embodiment, the first antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 45, or a variant or fragment thereof.
[0721] In one embodiment, the first antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 46.In one embodiment, the first antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 47, or a variant or fragment thereof.
[0722] In one embodiment, the first antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0723] In one embodiment, the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46.
[0724] In one embodiment, the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 59, and a light chain variable region comprising or consisting of SEQ ID No: 47.
[0725] In one embodiment, the first antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 201, or a variant or fragment thereof.
[0726] In one embodiment, the first antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 141, or a variant or fragment thereof.
[0727] In one embodiment, the first antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 201 and a light chain constant region comprising or consisting of SEQ ID No: 141.
[0728] Second antigen-binding domain (IL-13)
[0729] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 114, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises a CDR-H2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 115, or a variant or fragment thereof.
[0730] In one embodiment, the second antigen-binding domain comprises a CDR-H3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 116, or a variant or fragment thereof.
[0731] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115 and / or a CDR-H3 domain comprising or consisting of SEQ ID No: 116.
[0732] In one embodiment, the second antigen-binding domain comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 117, or a variant or fragment thereof.
[0733] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 119, or a variant or fragment thereof.
[0734] In one embodiment, the second antigen-binding domain comprises a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof.
[0735] In one embodiment, the second antigen-binding domain comprises a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
[0736] In one embodiment, the second antigen-binding domain comprises a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and / or a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0737] In one embodiment, the second antigen-binding domain comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 122, or a variant or fragment thereof.In one embodiment, the second antigen-binding domain comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the first antigen-binding domain comprises at least CDR-H3.
[0738] In one embodiment, the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0739] In one embodiment, the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
[0740] In one embodiment, the second antigen-binding domain comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 200, or a variant or fragment thereof.
[0741] In one embodiment, the second antigen-binding domain comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.
[0742] In one embodiment, the second antigen-binding domain comprises a heavy chain constant region comprising or consisting of SEQ ID No: 200 and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0743] In one embodiment, the disclosure provides a bispecific antibody or antigen-binding fragment thereof, comprising first and second antigen-binding domains consisting of heavy chain variable regions comprising CDR1, CDR2, and CDR3 sequences and light chain variable regions comprising CDR1, CDR2, and CDR3 sequences, wherein: the heavy chain variable regions CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 114, 58, 119, and 44, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the heavy chain variable regions CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 115, 50, 120, and 45, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the heavy chain variable regions CDR3 amino acid sequences are selected from thegroup consisting of SEQ ID NOs: 116, 51, 121, and 46, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions CDR1 amino acid sequences are selected from the group consisting of SEQ ID NOs: 119, 44, 114, and 58, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions CDR2 amino acid sequences are selected from the group consisting of SEQ ID NOs: 120, 45, 115, and 50, or variant sequences thereof comprising 1 , 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable regions of CDR3 amino acid sequences are selected from the group consisting of SEQ ID NOs: 121, 46, 116, and 51, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof.
[0744] In one embodiment, the disclosure provides a bispecific antibody or antigen-binding fragment thereof, comprising first and second antigen-binding domains comprising heavy chain variable regions and light chain variable regions, wherein: the heavy chain variable regions comprise an amino acid sequence that is at least 80%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 117, 59, 122, and 47; the light chain variable regions comprise an amino acid sequence that is at least 80%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 122, 47, 117, and 59. Alternatively the bispecific antibody or antigen-binding fragment thereof comprises first and second antigen-binding domains comprising heavy chain variable regions and light chain variable regions, wherein: the heavy chain variable regions comprise no more than 5 amino acid, or no more than 4 amino acid, or no more than 3 amino acid, or no more than 2 or no more than 1 amino acid change compared to the amino acid sequence selected from the group consisting of SEQ ID NOs: 117, 59, 122, and 47; the light chain variable regions comprise no more than 5 amino acid, or no more than 4 amino acid, or no more than 3 amino acid, or no more than 2 or no more than 1 amino acid change compared to the amino acid sequence selected from the group consisting of SEQ ID NOs: 122, 47, 117, and 59. In this context, the term "change" refers to insertions, deletions and / or substitutions.
[0745] The antibody of the invention may comprise or consist of any sequence as defined in Figure 16.In one embodiment, the bispecific antibody or antigen-binding fragment according to the first aspect, may comprise a mutated Fc fragment. For example, the bispecific antibody or antigen-binding fragment may be mutated by introducing amino acid substitutions into the Fc region, which silence or reduce the effector function of the antibody, and / or enhance Fc function. Accordingly, in one embodiment, the Fc fragment comprises one or more amino acid substitution that silences or reduces the effector function of the bispecific antibody or antigen-binding fragment thereof.
[0746] In one embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: L234A, L235A, and P329G, according to EU numbering. In one embodiment, the Fc fragment comprises the amino acid substitutions L234A, L235A, and P329G. In one embodiment, the Fc fragment comprises the amino acid substitutions L234A and L235A. Advantageously, these mutations result in Fc silencing.
[0747] In another embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: N325S and L328F, according to EU numbering. In one embodiment, the Fc fragment comprises the amino acid substitutions N325S and L328F.
[0748] In another embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: M252Y, S254T, and T256E, according to EU numbering. In one embodiment, the Fc fragment comprises the amino acid substitutions M252Y, S254T, and T256E. Advantageously, these mutations enhance the half-life of the bispecific antibody.
[0749] In another embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: M252Y, S254T, T256E, N325S, and L328F, according to EU numbering. In one embodiment, the Fc fragment comprises the amino acid substitutions M252Y, S254T, T256E, N325S, and L328F.
[0750] In another embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: L234F, L235E, M252Y, S254T, T256E, and P331S, according to EU numbering. In one embodiment, the Fc fragment comprises the amino acid substitutions L234F, L235E, M252Y, S254T, T256E, and P331S.In another embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: L234F, L235E and P331S, according to EU numbering. In one embodiment, the Fc fragment comprises the amino acid substitutions L234F, L235E and P331S.
[0751] In another embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: M428L and N434S. In one embodiment, the Fc fragment comprises the amino acid substitutions M428L and N434S.
[0752] In another embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: L235A and G237A. In one embodiment, the Fc fragment comprises the amino acid substitutions L235A and G237A.
[0753] In another embodiment, the Fc fragment of the first or second antigen-binding domain comprises a T366W amino acid substitution, and the Fc fragment of the first or second antigen-binding domain comprises the amino acid substitutions T366S, L368A, and Y407V, according to EU numbering. In one embodiment, the Fc fragment of the first antigen-binding domain comprises a T366W amino acid substitution, and the Fc fragment of the second antigen-binding domain comprises the amino acid substitutions T366S, L368A, and Y407V, according to EU numbering. In one embodiment, the Fc fragment of the second antigen-binding domain comprises a T366W amino acid substitution, and the Fc fragment of the first antigen-binding domain comprises the amino acid substitutions T366S, L368A, and Y407V, according to EU numbering.
[0754] In another embodiment, the Fc fragment of the first or second antigen-binding domain comprises a F405L amino acid substitution, and the Fc fragment of the first or second antigen-binding domain comprises a K409R amino acid substitution, according to EU numbering. In one embodiment, the Fc fragment of the first antigen-binding domain comprises a F405L amino acid substitution, and the Fc fragment of the second antigen-binding domain comprises a K409R amino acid substitution, according to EU numbering. In one embodiment, the Fc fragment of the second antigen-binding domain comprises a F405L amino acid substitution, and the Fc fragment of the first antigen-binding domain comprises a K409R amino acid substitution, according to EU numbering.In some embodiments, the bispecific antibody or antigen-binding fragment thereof is in the CrossMab VH-VL format. Advantageously, the bispecific antibody generated using the VH-VL orientation exhibits a higher purity than CrossMAb in other orientations expressed under the same conditions, in the absence of mutations introduced into a CrossMAb VH-VL domain.
[0755] As described above and in the Examples, the inventors have subjected a parent IL-18 antibody to affinity maturation in order to produce novel variants or mutants, with improved I potency and binding kinetics and / or affinity. The six CDR, VH, VL, CH and CL sequences of affinity matured IL-18 antibodies are summarised in the table shown in Figure 14.
[0756] Accordingly, in a sixteenth aspect of the invention, there is provided an antibody or antigen-binding fragment thereof that specifically binds to IL-18, and comprises:
[0757] (i) a CDR-H1 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 44, 80, 84, 101, 104, or 114, or a variant or fragment thereof;
[0758] (ii) a CDR-H2 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 45, 56, 62, 64, 68, 70, 72, 78, 82, 86, 88, 90, 102, or 115, or a variant or fragment thereof;
[0759] (iii) a CDR-H3 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 46, 60, 106, or 116, or a variant or fragment thereof;
[0760] (iv) a CDR-L1 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 49, 54, 58, 74, or 119, or a variant or fragment thereof;
[0761] (v) a CDR-L2 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 50, 93, or 120, or a variant or fragment thereof; and / or
[0762] (vi) a CDR-L3 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 51, 76, 94, 108, or 121, or a variant or fragment thereof.
[0763] In one embodiment, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 47, 57, 61, 63, 65, 69, 71, 73, 79, 81, 83, 85, 87, 89, 91, 92, 97, 98, 103, 105, 107, 110, 112, 113, or 117, or a variant or fragment thereof.In one embodiment, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 52, 55, 59, 67, 75, 77, 95, 96, 100, 109, 111, or 122, or a variant or fragment thereof.
[0764] In one embodiment, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.
[0765] In one embodiment, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of any one of SEQ ID Nos: 44, 80, 84, 101, 104, or 114, a CDR-H2 domain comprising or consisting of any one of SEQ ID Nos: 45, 56, 62, 64, 68, 70, 72, 78, 82, 86, 88, 90, 102, or 115, a CDR-H3 domain comprising or consisting of any one of SEQ ID Nos: 46, 60, 106, or 116, a CDR-L1 domain comprising or consisting of any one of SEQ ID Nos: 49, 54, 58, 74, or 119, a CDR-L2 domain comprising or consisting of any one of SEQ ID Nos: 50, 93, or 120, and a CDR-L3 domain comprising or consisting of any one of SEQ ID Nos: 51, 76, 94, 108, or 121.
[0766] In one embodiment, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising or consisting of any one of SEQ ID Nos: 47, 57, 61, 63, 65, 69, 71, 73, 79, 81, 83, 85, 87, 89, 91, 92, 97, 98, 103, 105, 107, 110, 112, 113, or 117, and a light chain variable region comprising or consisting of any one of SEQ ID Nos: 52, 55, 59, 67, 75, 77, 95, 96, 100, 109, 111, or 122.
[0767] In one embodiment, the antibody or antigen-binding fragment thereof comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 48, 99, 118 or 199, or a variant or fragment thereof.
[0768] In one embodiment, the antibody or antigen-binding fragment thereof comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.In one embodiment, the antibody or antigen-binding fragment thereof comprises a heavy chain constant region comprising or consisting of SEQ ID No: 48, 99, or 118, and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0769] In one embodiment, the disclosure provides an antibody or antigen-binding fragment thereof, consisting of a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences, wherein: the heavy chain variable region CDR1 amino acid sequence is selected from the group consisting of SEQ ID NOs: 44, 80, 84, 101, 104, and 114, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the heavy chain variable region CDR2 amino acid sequence is selected from the group consisting of SEQ ID NOs: 45, 56, 62, 64, 68, 70, 72, 78, 82, 86, 88, 90, 102, and 115, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the heavy chain variable region CDR3 amino acid sequence is selected from the group consisting of SEQ ID NOs: 46, 60, 106, and 116, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable region CDR1 amino acid sequence is selected from the group consisting of SEQ ID NOs: 49, 54, 58, 74, and 119, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable region CDR2 amino acid sequence is selected from the group consisting of SEQ ID NOs: 50, 93, and 120, or variant sequences thereof comprising 1 , 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable region CDR3 amino acid sequence is selected from the group consisting of SEQ ID NOs: 51, 76, 94, 108, and 121, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof.
[0770] In one embodiment, the disclosure provides an antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein: the heavy chain variable region comprises an amino acid sequence that is at least 80%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 47, 57, 61, 63, 65, 69, 71, 73, 79, 81, 83, 85, 87, 89, 91, 92, 97, 98, 103, 105, 107, 110, 112, 113, and 117; the light chain variable region comprises an amino acid sequence that is at least 80%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 55, 59, 67, 75, 77, 95, 96, 100, 109, 111, and 122. Alternatively the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variableregion, wherein: the heavy chain variable region comprises no more than 5 amino acid, or no more than 4 amino acid, or no more than 3 amino acid, or no more than 2 or no more than 1 amino acid change compared to the amino acid sequence selected from the group consisting of SEQ ID NOs: 47, 57, 61, 63, 65, 69, 71, 73, 79, 81, 83, 85, 87, 89, 91, 92, 97, 98, 103, 105, 107, 110, 112, 113, and 117,; the light chain variable region comprises no more than 5 amino acid, or no more than 4 amino acid, or no more than 3 amino acid, or no more than 2 or no more than 1 amino acid change compared to the amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 55, 59, 67, 75, 77, 95, 96, 100, 109, 111, and 122. In this context, the term "change" refers to insertions, deletions and / or substitutions.
[0771] The antibody or antigen-binding fragment thereof of the invention may comprise or consist of any sequence as defined in Figure 14.
[0772] Additionally, as described above and in the Examples, the inventors have subjected a parent IL-13 antibody to affinity maturation in order to produce novel variants or mutants, with improved activity and binding affinity. The six CDR, VH, VL, CH and CL sequences of affinity matured IL-13 antibodies are summarised in the table shown in Figure 15.
[0773] Accordingly, in a seventeenth aspect of the invention, there is provided an antibody or antigen-binding fragment thereof that specifically binds to IL-13, and comprises:
[0774] (i) a CDR-H1 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 114 or 131, or a variant or fragment thereof;
[0775] (ii) a CDR-H2 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 123 or 115, or a variant or fragment thereof;
[0776] (iii) a CDR-H3 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 116 or 129, or a variant or fragment thereof;
[0777] (iv) a CDR-L1 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 125, 127, or 133, or a variant or fragment thereof;
[0778] (v) a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof; and / or (vi) a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.In one embodiment, the antibody or antigen-binding fragment thereof comprises a heavy chain variable (VH) region comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 124, 130, or 132, or a variant or fragment thereof.
[0779] In one embodiment, the antibody or antigen-binding fragment thereof comprises a light chain variable (VL) region comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 126, 128, or 134, or a variant or fragment thereof.
[0780] In one embodiment, the antibody or antigen-binding fragment thereof comprises at least one, at least two, at least three, at least four, at least five, or at least six CDRs. In one embodiment, the antibody or antigen-binding fragment thereof comprises at least CDR-H3.
[0781] In one embodiment, the antibody or antigen-binding fragment thereof comprises a CDR-H1 domain comprising or consisting of any one of SEQ ID Nos: 114 or 131, a CDR-H2 domain comprising or consisting of any one of SEQ ID Nos: 123 or 115, a CDR-H3 domain comprising or consisting of any one of SEQ ID Nos: 116 or 129, a CDR-L1 domain comprising or consisting of any one of SEQ ID Nos: 125, 127, or 133, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
[0782] In one embodiment, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising or consisting of any one of SEQ ID Nos: 124, 130, or 132, and a light chain variable region comprising or consisting of any one of SEQ ID Nos: 126, 128, or 134.
[0783] In one embodiment, the antibody or antigen-binding fragment thereof comprises a heavy chain constant (HC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 118, or a variant or fragment thereof.
[0784] In one embodiment, the antibody or antigen-binding fragment thereof comprises a light chain constant (LC) region comprising or consisting of a sequence as substantially set out in SEQ ID No: 53, or a variant or fragment thereof.In one embodiment, the antibody or antigen-binding fragment thereof comprises a heavy chain constant region comprising or consisting of SEQ ID No: 118, and a light chain constant region comprising or consisting of SEQ ID No: 53.
[0785] In one embodiment, the disclosure provides an antibody or antigen-binding fragment thereof, consisting of a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences, wherein: the heavy chain variable region CDR1 amino acid sequence is selected from the group consisting of SEQ ID NOs: 114 and 131, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the heavy chain variable region CDR2 amino acid sequence is selected from the group consisting of SEQ ID NOs: 123 and 115, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the heavy chain variable region CDR3 amino acid sequence is selected from the group consisting of SEQ ID NOs: 116 and 129, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable region CDR1 amino acid sequence is selected from the group consisting of SEQ ID NOs: 125, 127, and 133, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable region CDR2 amino acid sequence is selected from the group consisting of SEQ ID NOs: 120, or variant sequences thereof comprising 1 , 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof; the light chain variable region CDR3 amino acid sequence is selected from the group consisting of SEQ ID NOs: 121, or variant sequences thereof comprising 1, 2, 3, 4 or 5 amino acid changes, and conservative modifications thereof.
[0786] In one embodiment, the disclosure provides an antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein: the heavy chain variable region comprises an amino acid sequence that is at least 80%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 124, 130, and 132; the light chain variable region comprises an amino acid sequence that is at least 80%, or at least 90% (preferably at least 95, 97 or 99%) identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 126, 128, and 134.
[0787] Alternatively the antibody or antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein: the heavy chain variable region comprises no more than 5 amino acid, or no more than 4 amino acid, or no more than 3 amino acid, or no more than 2 or no more than 1 amino acidchange compared to the amino acid sequence selected from the group consisting of SEQ ID NOs: 124, 130, and 132; the light chain variable region comprises no more than 5 amino acid, or no more than 4 amino acid, or no more than 3 amino acid, or no more than 2 or no more than 1 amino acid change compared to the amino acid sequence selected from the group consisting of SEQ ID NOs: 126, 128, and 134. In this context, the term "change" refers to insertions, deletions and / or substitutions.
[0788] The antibody or antigen-binding fragment thereof of the invention may comprise or consist of any sequence as defined in Figure 15.
[0789] In one embodiment, the IL-18 and / or IL-13 affinity matured antibody or antigenbinding fragment thereof, may comprise a mutated Fc fragment. For example, the antibody or antigen-binding fragment may be mutated by introducing amino acid substitutions into the Fc region, which silence or reduce the effector function of the antibody, enhance Fc function and / or extend half-life and improve the PK properties. Accordingly, in one embodiment, the Fc fragment comprises one or more amino acid substitution that silences or reduces the effector function of the antibody or antigenbinding fragment thereof.
[0790] In one embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: L234A, L235A, and P329G, according to EU numbering. In one embodiment, the Fc fragment comprises the amino acid substitutions L234A, L235A, and P329G. In one embodiment, the Fc fragment comprises the amino acid substitutions L234A and L235A. Advantageously, these mutations result in Fc silencing.
[0791] In another embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: N325S and L328F, according to EU numbering. In one embodiment, the Fc fragment comprises the amino acid substitutions N325S and L328F.
[0792] In another embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: M252Y, S254T, and T256E, according to EU numbering. In one embodiment, the Fc fragment comprises the amino acid substitutions M252Y, S254T, and T256E. Advantageously, these mutations enhance the half-life of the bispecific antibody.In another embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: M252Y, S254T, T256E, N325S, and L328F, according to EU numbering. In one embodiment, the Fc fragment comprises the amino acid substitutions M252Y, S254T, T256E, N325S, and L328F.
[0793] In another embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: L234F, L235E, M252Y, S254T, T256E, and P331S, according to EU numbering. In one embodiment, the Fc fragment comprises the amino acid substitutions L234F, L235E, M252Y, S254T, T256E, and P331S.
[0794] In another embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: L234F, L235E and P331S, according to EU numbering. In one embodiment, the Fc fragment comprises the amino acid substitutions L234F, L235E and P331S.
[0795] In another embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: M428L and N434S. In one embodiment, the Fc fragment comprises the amino acid substitutions M428L and N434S.
[0796] In another embodiment, the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: L235A and G237A. In one embodiment, the Fc fragment comprises the amino acid substitutions L235A and G237A.
[0797] Advantageously, the anti-IL-18 and anti-IL-13 activity of the bispecific antibody or antigen-binding fragment thereof according to the first aspect, and the anti-IL-18 or anti-IL-13 activity of the affinity matured anti-IL-18 and IL-13 antibodies of the sixteenth and seventeenth aspects, of the invention, means that they have utility as a therapeutic agent in their own right, and may be used in the treatment, amelioration or prevention of diseases associated with excessive or dysregulated IL-18 and / or IL-13 activity, such as asthma, allergic rhinitis, atopic dermatitis, fibrosis, and other chronic inflammatory disorders.
[0798] Accordingly, in a second aspect of the invention, there is provided the bispecific antibody or antigen-binding fragment thereof according to the first aspect, or theantibody or antigen-binding fragment thereof according to the sixteenth or seventeenth aspect, for use in therapy.
[0799] In a third aspect of the invention, there is provided the bispecific antibody or antigenbinding fragment thereof according to the first aspect, or the antibody or antigenbinding fragment thereof according to the sixteenth or seventeenth aspect, for use in treating, preventing or ameliorating a condition mediated by IL-18 and / or IL-13.
[0800] According to a fourth aspect of the invention, there is provided a method of treating, preventing or ameliorating a condition mediated by IL-18 and / or IL-13 in a subject, the method comprising administering, or having administered, to a patient in need of such treatment, a therapeutically effective amount of the bispecific antibody or antigen-binding fragment thereof according to the first aspect, or the antibody or antigen-binding fragment thereof according to the sixteenth or seventeenth aspect.
[0801] The phrase "condition mediated by IL-18 and / or IL-13" encompasses all diseases and medical conditions in which IL-13 and / or IL-18, whether directly or indirectly, in the disease or medical condition, contribute to the causation, development, progress, persistence or pathology of the disease or condition. Accordingly, these terms include conditions associated with or characterized by aberrant IL-13 and IL-18 levels and / or diseases or conditions that can be treated by reducing or suppressing IL-13 and IL- 18-induced activity in target cells or tissues. Pathological disorders mediated by IL-13 and IL-18 include autoimmune diseases and / or inflammatory conditions and disorders having an IL-13 and IL-18 component.
[0802] In some embodiments, the condition is associated with inappropriate IL-18 and / or IL-13 expression. In some embodiments, the condition is associated with inappropriate IL-18 and / or IL-13 signalling.
[0803] The condition mediated by IL-18 and / or IL-13 may be selected from the group consisting of: Atopic Dermatitis (AD I Eczema), Systemic Juvenile Idiopathic Arthritis (sJIA), Adult-Onset Still's Disease (AOSD), Macrophage Activation Syndrome (MAS), Hemophagocytic Lymphohistiocytosis (HLH), Inflammatory Bowel Disease (IBD) including Crohn's Disease and Ulcerative Colitis, Multiple Sclerosis (MS), Neuroinflammation, Alzheimer's Disease, Chronic Obstructive Pulmonary Disease (COPD), Asthma including Allergic Asthma, Allergic Rhinitis (Hay Fever), Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Urticaria (Chronic Hives), Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Eosinophilic Pneumonia, SystemicLupus Erythematosus (SLE), Primary Sjogren's Syndrome, Hypereosinophilic Syndrome (HES), Pemphigus, Psoriasis, Ankylosing Spondylitis, Rheumatoid Arthritis (RA), Fibrosis including Pulmonary Fibrosis and Liver Fibrosis, Infections, Sepsis, and Cytokine Storm Syndromes.
[0804] In some embodiments, the bispecific antibody or antigen-binding fragment thereof inhibits Thl and Th2 cytokine pathways.
[0805] In some embodiments, the bispecific antibody or antigen-binding fragment thereof inhibits IL-18-induced IFN-y and / or IL-13-induced CCL17 (TARC) release.
[0806] In some embodiments, the bispecific antibody or antigen-binding fragment thereof inhibits IL-13-induced STAT6 signalling.
[0807] In some embodiments, the bispecific antibody or antigen-binding fragment thereof inhibits IL-13-induced TF1 cell proliferation.
[0808] In some embodiments, the bispecific antibody or antigen-binding fragment thereof inhibits IL-18-induced IFN-y release.
[0809] In some embodiments, the bispecific antibody or antigen-binding fragment thereof exhibits low or reduced poly-reactivity. Advantageously, therefore, the claimed bispecific antibody will have improved pharmacokinetic properties, reduced clearance and half-life, and a better safety profile.
[0810] In some embodiments, the bispecific antibody or antigen-binding fragment thereof binds with high affinity to FcRn at pH 6.0. Advantageously, this contributes to the antibody recycling mechanism and extended half-life.
[0811] In some embodiments, the bispecific antibody or antigen-binding fragment thereof exhibits silencing of Fc functions and improved developability characteristics, such as, but not limited to yield, purity, stability, propensity for self-aggregation and concentration.
[0812] It will be appreciated that antibodies or fragments thereof according to the invention (collectively referred to herein as "agents") may be used in a monotherapy (e.g. the use of a bispecific antibody or antigen binding fragment thereof alone, or antibody or antigen binding fragment thereof alone), for treating, ameliorating or preventing a condition mediated by IL-18 and / or IL-13. Alternatively, agents according to theinvention may be used as an adjunct to, or in combination with, known therapies for treating, ameliorating, or preventing a condition mediated by IL-18 and / or IL-13, such as JAK inhibitors (e.g. Tofacitinib, Baricitinib, Upadacitinib), corticosteroids (e.g.
[0813] Prednisone, Budesonide), Anti-IgE or IL-5 therapies (e.g. Omalizumab, Mepolizumab, Benralizumab, Depekeimab), anti-TNFs / IL-23s (e.g. Infliximab, Adalimumab (anti-TNF), Ustekinumab, Guselkumab (anti-IL-23)), or anti-IL4R (dupilumab).
[0814] The agents according to the invention may be combined in compositions having a number of different forms depending, in particular, on the manner in which the composition is to be used. Thus, for example, the composition may be in the form of a powder, tablet, capsule, liquid, ointment, cream, gel, hydrogel, aerosol, spray, micellar solution, transdermal patch, liposome suspension or any other suitable form that may be administered to a person or animal in need of treatment. It will be appreciated that the vehicle of medicaments according to the invention should be one which is well-tolerated by the subject to whom it is given.
[0815] Medicaments comprising agents of the invention may be used in a number of ways. For instance, oral administration may be required, in which case the agents may be contained within a composition that may, for example, be ingested orally in the form of a tablet, capsule or liquid. Compositions comprising agents and medicaments of the invention may be administered by inhalation (e.g. intranasally). Compositions may also be formulated for topical use. For instance, creams or ointments may be applied to the skin.
[0816] Agents and medicaments according to the invention may also be incorporated within a slow- or delayed-release device. Such devices may, for example, be inserted on or under the skin, and the medicament may be released over weeks or even months. The device may be located at least adjacent the treatment site. Such devices may be particularly advantageous when long-term treatment with agents used according to the invention is required and which would normally require frequent administration (e.g. at least daily injection).
[0817] In one embodiment, agents and medicaments according to the invention may be administered to a subject by injection into the blood stream or directly into a site requiring treatment. Injections may be intravenous (bolus or infusion) or subcutaneous (bolus or infusion), or intradermal (bolus or infusion).It will be appreciated that the amount of the antibodies and fragments (i.e. agent) that is required is determined by its biological activity and bioavailability, which in turn depends on the mode of administration, the physiochemical properties of the agent, and whether it is being used as a monotherapy or in a combined therapy. The frequency of administration will also be influenced by the half-life of the agent within the subject being treated. Optimal dosages to be administered may be determined by those skilled in the art, and will vary with the particular agent in use, the strength of the pharmaceutical composition, the mode of administration, and the advancement of the condition. Additional factors depending on the particular subject being treated will result in a need to adjust dosages, including subject age, weight, gender, diet, and time of administration.
[0818] Generally, a daily dose of between O.Olpg / kg of body weight and lOOmg / kg of body weight of agent according to the invention may be used for treating, ameliorating, or preventing the condition mediated by IL-18 and / or IL-13, depending upon which agent. More typically, the daily dose of agent is between Ipg / kg of body weight and lOOmg / kg of body weight, more typically between lOpg / kg and lOmg / kg body weight, and most typically between approximately lOOpg / kg and lOmg / kg body weight.
[0819] The agents may be administered before, during or after onset of the condition mediated by IL-18 and / or IL-13. Daily doses may be given as a single administration (e.g. a single daily injection). Alternatively, the agents may require administration twice or more times during a day. As an example, agents may be administered as two (or more depending upon the severity of the condition mediated by IL-18 and / or IL-13 being treated) daily doses of between 0.07 pg and 700 mg (i.e. assuming a body weight of 70 kg). A patient receiving treatment may take a first dose upon waking and then a second dose in the evening (if on a two dose regime) or at 3- or 4-hourly intervals thereafter. Alternatively, a slow release device may be used to provide optimal doses of agents according to the invention to a patient without the need to administer repeated doses. Known procedures, such as those conventionally employed by the pharmaceutical industry (e.g. in vivo experimentation, clinical trials, etc.), may be used to form specific formulations of the agents according to the invention and precise therapeutic regimes (such as daily doses of the agents and the frequency of administration).
[0820] In a fifth aspect of the invention, there is provided a pharmaceutical composition comprising the bispecific antibody or antigen-binding fragment thereof according tothe first aspect, or the antibody or antigen-binding fragment thereof according to the sixteenth or seventeenth aspect, and optionally a pharmaceutically acceptable vehicle.
[0821] The pharmaceutical composition may be anti-IL-18 and / or anti-IL-13, i.e. a pharmaceutical formulation used in the therapeutic amelioration, prevention or treatment of a condition mediated by IL-18 and / or IL-13.
[0822] The invention also provides in a sixth aspect, a process for making the pharmaceutical composition according to the fifth aspect, the process comprising combining a therapeutically effective amount of the bispecific antibody or antigen-binding fragment thereof as defined in the first aspect, or the antibody or antigen-binding fragment thereof according to the sixteenth or seventeenth aspect, with a pharmaceutically acceptable vehicle.
[0823] The bispecific antibody or antigen-binding fragment thereof may be as defined with respect to the first aspect. The antibody or antigen-binding fragment thereof may be as defined with respect to the sixteenth or seventeenth aspect.
[0824] A "subject" may be a vertebrate, mammal, or domestic animal. Hence, medicaments according to the invention may be used to treat any mammal, for example livestock (e.g. a horse), pets, or may be used in other veterinary applications. In some embodiments, the subject is a human being.
[0825] A "therapeutically effective amount" of the bispecific antibody or antigen-binding fragment thereof is any amount which, when administered to a subject, is the amount of agent that is needed to treat the condition mediated by IL-18 and / or IL-13, or produce the desired effect.
[0826] For example, the therapeutically effective amount of bispecific antibody or fragment thereof used may be from about 0.1 ng / kg to about 100 mg / kg, and typically from about 1 ng / kg to about 10 mg / kg. In some embodiments, the amount of antibody or fragment is an amount from about 10 ng / kg to about 10 mg / kg, and most typically from about 50 ng / kg to about 5 mg / kg.
[0827] A "pharmaceutically acceptable vehicle" as referred to herein, is any known compound or combination of known compounds that are known to those skilled in the art to be useful in formulating pharmaceutical compositions.In one embodiment, the pharmaceutically acceptable vehicle may be a solid, and the composition may be in the form of a powder or tablet. A solid pharmaceutically acceptable vehicle may include one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, dyes, fillers, glidants, compression aids, inert binders, sweeteners, preservatives, dyes, coatings, or tabletdisintegrating agents. The vehicle may also be an encapsulating material. In powders, the vehicle is a finely divided solid that is in admixture with the finely divided active agents according to the invention. In tablets, the active agent may be mixed with a vehicle having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets may contain up to 99% of the active agents. Suitable solid vehicles include, for example calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins. In another embodiment, the pharmaceutical vehicle may be a gel and the composition may be in the form of a cream or the like.
[0828] However, the pharmaceutical vehicle may be a liquid, and the pharmaceutical composition is in the form of a solution. Liquid vehicles are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active agent according to the invention may be dissolved or suspended in a pharmaceutically acceptable liquid vehicle such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid vehicle can contain other suitable pharmaceutical additives such as solubilisers, emulsifiers, buffers, preservatives, sweeteners, flavouring agents, suspending agents, thickening agents, colours, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid vehicles for oral and parenteral administration include water (partially containing additives as above, e.g. cellulose derivatives, sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the vehicle can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid vehicles are useful in sterile liquid form compositions for parenteral administration. The liquid vehicle for pressurized compositions can be a halogenated hydrocarbon or other pharmaceutically acceptable propellant.
[0829] Liquid pharmaceutical compositions, which are sterile solutions or suspensions, can be utilized by, for example, intramuscular, intrathecal, epidural, intraperitoneal, intravenous and particularly subcutaneous injection. The agent may be prepared as asterile solid composition that may be dissolved or suspended at the time of administration using sterile water, saline, or other appropriate sterile injectable medium.
[0830] The agents and compositions of the invention may be administered orally in the form of a sterile solution or suspension containing other solutes or suspending agents (for example, enough saline or glucose to make the solution isotonic), bile salts, acacia, gelatin, sorbitan monoleate, polysorbate 80 (oleate esters of sorbitol and its anhydrides copolymerized with ethylene oxide) and the like. The agents used according to the invention can also be administered orally either in liquid or solid composition form. Compositions suitable for oral administration include solid forms, such as pills, capsules, granules, tablets, and powders, and liquid forms, such as solutions, syrups, elixirs, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions, and suspensions.
[0831] In a seventh aspect of the invention, there is provided one or more polynucleotide sequence encoding the bispecific antibody or antigen binding fragment thereof as defined in the first aspect, or the antibody or antigen-binding fragment thereof according to the sixteenth or seventeenth aspect.
[0832] In some embodiments, a nucleotide sequence encoding the first antigen-binding domain (IL-18) and a nucleotide sequence encoding the second antigen-binding domain (IL-13) are disposed on separate polynucleotides. In some embodiments, a nucleotide sequence encoding the heavy chains of the first (IL-18) and second (IL-13) antigen-binding domain are disposed on a first polynucleotide, and a nucleotide sequence encoding the light chains of the first (IL-18) and second (IL-13) antigenbinding domains are disposed on a second polynucleotide. In some embodiments, a nucleotide sequence encoding the heavy chain of the first (IL-18) antigen-binding domain and the light chain of the second (IL-13) antigen-binding domain are disposed on a first polynucleotide, and a nucleotide sequence encoding the light chain of the first (IL-18) antigen-binding domain and the heavy chain of the second (IL-13) antigen-binding domain are disposed on a second polynucleotide.
[0833] In some embodiments, a nucleotide sequence encoding the first antigen-binding domain (IL-18) and a nucleotide sequence encoding the second antigen-binding domain (IL-13) are disposed on a single polynucleotide.In an eighth aspect of the invention, there is provided an expression cassette comprising one or more polynucleotide sequence according to the seventh aspect.
[0834] The polynucleotide sequence(s) encoding the bispecific antibody or antigen binding fragment thereof of the invention is typically harboured in a recombinant vector, for example a recombinant vector for delivery into a host cell of interest to enable production of the bispecific antibody or antigen binding fragment thereof.
[0835] Accordingly, in a ninth aspect of the invention, there is provided a recombinant vector comprising the expression cassette according to the eighth aspect.
[0836] The vector encoding the bispecific antibody or antigen binding fragment thereof of the first aspect, or the antibody or antigen binding fragment thereof of the sixteenth or seventeenth aspect, may for example be a plasmid, cosmid or phage and / or be a viral vector. Such recombinant vectors are highly useful in the delivery systems of the invention for transforming cells with the nucleotide sequences. The nucleotide sequences may be a DNA sequence, and it is this DNA sequence which encodes the bispecific antibody or antigen binding fragment thereof sequence forming the bispecific antibody or antigen binding fragment thereof of the first aspect, or the antibody or antigen binding fragment thereof of the sixteenth or seventeenth aspect.
[0837] Recombinant vectors encoding the bispecific antibody or antigen binding fragment thereof of the first aspect, or the antibody or antigen binding fragment thereof of the sixteenth or seventeenth aspect, may also include other functional elements. For example, they may further comprise a variety of other functional elements including a suitable promoter for initiating transgene expression upon introduction of the vector in a host cell. For instance, the vector may be capable of autonomously replicating in the nucleus of the host cell. In this case, elements which induce or regulate DNA replication may be required in the recombinant vector. Alternatively, the recombinant vector may be designed such that it integrates into the genome of a host cell. In this case, DNA sequences which favour targeted integration (e.g. by homologous recombination) are envisaged. Suitable promoters may include the SV40 promoter, CMV, EFla, PGK, viral long terminal repeats, as well as inducible promoters, such as the Tetracycline inducible system, as examples. The cassette or vector may also comprise a terminator, such as the Beta globin, SV40 polyadenylation sequences or synthetic polyadenylation sequences. The recombinant vector may also comprise a promoter or regulator or enhancer to control expression of the nucleic acid as required.The vector may also comprise DNA coding for a gene that may be used as a selectable marker in the cloning process, i.e. to enable selection of cells that have been transfected or transformed, and to enable the selection of cells harbouring vectors incorporating heterologous DNA. For example, ampicillin, neomycin, puromycin or chloramphenicol resistance is envisaged. Alternatively, the selectable marker gene may be in a different vector to be used simultaneously with the vector containing the transgene. The cassette or vector may also comprise DNA involved with regulating expression of the nucleotide sequence, or for targeting the expressed polypeptide to a certain part of the host cell.
[0838] Purified vector may be inserted directly into a host cell by suitable means, e.g. direct endocytotic uptake. The vector may be introduced directly into a host cell (e.g. a eukaryotic or prokaryotic cell) by transfection, infection, electroporation, microinjection, cell fusion, protoplast fusion, calcium phosphate, cationic lipid-based lipofection, polymer or dendrimer-based methods or ballistic bombardment.
[0839] Alternatively, vectors of the invention may be introduced directly into a host cell using a particle gun.
[0840] Alternatively, the delivery system may provide the polynucleotide to the host cell without it being incorporated in a vector. For instance, the nucleic acid molecule may be incorporated within a liposome or virus particle. Alternatively, a "naked" polynucleotide may be inserted into a host cell by a suitable means e.g. direct endocytotic uptake.
[0841] In a tenth aspect of the invention, there is provided a host cell comprising the one or more polynucleotide sequence according to the seventh aspect, the expression cassette according to the eighth aspect, or the vector according to the ninth aspect.
[0842] The host cell may be a eukaryotic or prokaryotic host cell. In some embodiments, the host cell is a eukaryotic host cell. In some embodiments, the host cell is a mammalian host cell such as NSO murine myeloma cells, PER.C6® human cells, Human embryonic kidney 293 cells or Chinese hamster ovary (CHO) cells. In some embodiments, the host cell is a CHO cell.
[0843] In an eleventh aspect, there is provided a method of preparing the bispecific antibody or antigen binding fragment according to the first aspect, or the antibody or antigen-binding fragment thereof according to the sixteenth or seventeenth aspect, the method comprising:
[0844] a) introducing, into a host cell, the vector of the ninth aspect; and
[0845] b) culturing the host cell under conditions to result in the production of the bispecific antibody or antigen binding fragment according to the first aspect, or the antibody or antigen-binding fragment thereof according to the sixteenth or seventeenth aspect.
[0846] The host cell of step a) may be a eukaryotic or prokaryotic host cell. In some embodiments, the host cell is a eukaryotic host cell. In some embodiments, the host cell is a mammalian host cell such as NSO murine myeloma cells, PER.C6® human cells, Human embryonic kidney 293 cells or Chinese hamster ovary (CHO) cells. In some embodiments, the host cell is a CHO cell.
[0847] The method may further comprise (c) harvesting, centrifuging and / or filtering the cell culture media to obtain a cell culture supernatant comprising the bispecific antibody or antigen binding fragment thereof.
[0848] The method may further comprise (d) separating and purifying the bispecific antibody or antigen binding fragment thereof from the cell culture supernatant. In some embodiments, purification is performed by at least one chromatographic step.
[0849] Suitable chromatographic steps include affinity chromatography and / or ion exchange chromatography. In some embodiments, affinity chromatography is protein A chromatography. Ion exchange chromatography may be anionic exchange chromatography and / or cationic exchange chromatography.
[0850] In some embodiments, step (d) comprises separating and purifying the bispecific antibody or antigen binding fragment thereof from the cell culture supernatant by: i) protein A chromatography;
[0851] ii) anionic exchange chromatography; and / or
[0852] iii) cationic exchange chromatography.
[0853] The method may further comprise (e) filtering the purified bispecific antibody or antigen binding fragment thereof resulting from step (d). In some embodiments, step (e) comprises virus filtration. Thus, in some embodiments, the purified bispecific antibody or antigen binding fragment thereof resulting from step (d) is filtered using avirus filtration membrane. Suitable membranes would be known to those skilled in the art.
[0854] As discussed herein, IL-18 and IL-13 expression is increased in several IL-18- and IL-13-mediated conditions. Thus, given that the antibodies of the invention are able to bind to IL-18 and IL-13, the bispecific antibodies or antigen-binding fragment thereof may be used as a robust diagnostic tool by detecting the presence, and determining the concentration, of IL-18 and IL-13.
[0855] In one aspect, there is provided a method of detecting the presence of IL-18 and / or IL-13 in a biological sample, comprising contacting the biological sample with the bispecific antibody or antigen-binding fragment thereof according to the first aspect, or the antibody or antigen-binding fragment thereof according to the sixteenth or seventeenth aspect.
[0856] In a twelfth aspect, there is provided the bispecific antibody or antigen-binding fragment according to the first aspect, or the antibody or antigen-binding fragment thereof according to the sixteenth or seventeenth aspect, for use in diagnosis or prognosis.
[0857] According to a thirteenth aspect of the invention, there is provided the bispecific antibody or antigen-binding fragment according to the first aspect, or the antibody or antigen-binding fragment thereof according to the sixteenth or seventeenth aspect, for use in diagnosing or prognosing a condition mediated by IL-18 and / or IL-13.
[0858] According to a fourteenth aspect, there is provided a method of diagnosing or prognosing a condition mediated by IL-18 and / or IL-13 in a subject, the method comprising detecting IL-18 and / or IL-13 in a biological sample obtained from the subject with the bispecific antibody or antigen-binding fragment according to the first aspect, or the antibody or antigen-binding fragment thereof according to the sixteenth or seventeenth aspect.
[0859] The condition mediated by IL-18 and / or IL-13 may be selected from the group consisting of: Atopic Dermatitis (AD I Eczema), Systemic Juvenile Idiopathic Arthritis (sJIA), Adult-Onset Still's Disease (AOSD), Macrophage Activation Syndrome (MAS), Hemophagocytic Lymphohistiocytosis (HLH), Inflammatory Bowel Disease (IBD) including Crohn's Disease and Ulcerative Colitis, Multiple Sclerosis (MS), Neuroinflammation, Alzheimer's Disease, Chronic Obstructive Pulmonary Disease(COPD), Asthma including Allergic Asthma, Allergic Rhinitis (Hay Fever), Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Urticaria (Chronic Hives), Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Eosinophilic Pneumonia, Systemic Lupus Erythematosus (SLE), Primary Sjogren's Syndrome, Hypereosinophilic Syndrome (HES), Pemphigus, Psoriasis, Ankylosing Spondylitis, Rheumatoid Arthritis (RA), Fibrosis including Pulmonary Fibrosis and Liver Fibrosis, Infections, Sepsis, and Cytokine Storm Syndromes.
[0860] The method may be an in vitro or ex vivo method. In some embodiments, the method is an in vitro method.
[0861] The use or method may comprise determining the level of expression of IL-18 and IL-13 in a subject, typically wherein an increase in the concentration of IL-18 and IL-13 in the biological sample when compared to a reference concentration from a healthy control population is indicative of the condition mediated by IL-18 and / or IL-13 or a poor prognosis.
[0862] According to a fifteenth aspect of the invention, there is provided a kit for diagnosing a subject suffering from a condition mediated by IL-18 and / or IL-13, or for providing a prognosis of the subject's condition, the kit comprising the bispecific antibody or antigen-binding fragment thereof according to the first aspect, or the antibody or antigen-binding fragment thereof according to the sixteenth or seventeenth aspect, for detecting IL-18 and / or IL-13 in a sample from a test subject.
[0863] The condition mediated by IL-18 and / or IL-13 may be selected from the group consisting of: Atopic Dermatitis (AD I Eczema), Systemic Juvenile Idiopathic Arthritis (sJIA), Adult-Onset Still's Disease (AOSD), Macrophage Activation Syndrome (MAS), Hemophagocytic Lymphohistiocytosis (HLH), Inflammatory Bowel Disease (IBD) including Crohn's Disease and Ulcerative Colitis, Multiple Sclerosis (MS), Neuroinflammation, Alzheimer's Disease, Chronic Obstructive Pulmonary Disease (COPD), Asthma including Allergic Asthma, Allergic Rhinitis (Hay Fever), Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Urticaria (Chronic Hives), Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Eosinophilic Pneumonia, Systemic Lupus Erythematosus (SLE), Primary Sjogren's Syndrome, Hypereosinophilic Syndrome (HES), Pemphigus, Psoriasis, Ankylosing Spondylitis, Rheumatoid Arthritis (RA), Fibrosis including Pulmonary Fibrosis and Liver Fibrosis, Infections, Sepsis, and Cytokine Storm Syndromes.Prognosis may relate to determining the therapeutic outcome in a subject that has been diagnosed with a condition mediated by IL-18 and / or IL-13. Prognosis may relate to predicting the rate of progression or improvement and / or the duration of the condition mediated by IL-18 and / or IL-13 in a subject, the probability of survival, and / or the efficacy of various treatment regimes. Thus, a poor prognosis may be indicative of progression of the condition mediated by IL-18 and / or IL-13, low probability of survival and reduced efficacy of a treatment regime. A favourable prognosis may be indicative of resolution of the condition mediated by IL-18 and / or IL-13, high probability of survival and increased efficacy of a treatment regime.
[0864] The kit may further comprise instructions for use and / or a receptacle for obtaining a biological sample from a subject.
[0865] In some embodiments, the sample comprises a biological sample. The sample may be any material that is obtainable from a subject from which protein is obtainable.
[0866] The biological sample may be tissue or a biological fluid. The biological sample may be any material that is obtainable from the subject from which endothelial, smooth muscle and / or interstitial cells are obtainable. Furthermore, the sample may be blood, plasma, serum, spinal fluid, urine, sweat, saliva, tears, breast aspirate, breast milk, prostate fluid, seminal fluid, vaginal fluid, stool, cervical scraping, cytes, amniotic fluid, intraocular fluid, mucous, moisture in breath, animal tissue, cell lysates, tumour tissue, hair, skin, buccal scrapings, lymph, interstitial fluid, nails, bone marrow, cartilage, prions, bone powder, ear wax, lymph, granuloma, cancer biopsy or combinations thereof.
[0867] The sample may comprise blood, urine, tissue etc. In one embodiment, the biological sample comprises a blood sample. The blood may be venous or arterial blood. Blood samples may be assayed immediately. Alternatively, the blood sample may be stored at low temperatures, for example in a fridge or even frozen before the method is conducted. Alternatively, the blood sample may be stored at room temperature, for example between 18 to 22 degrees Celsius, before the method is conducted. The blood sample may comprise comprises blood serum. The blood sample may comprise blood plasma. In some embodiments, however the detection is carried out on whole blood and most typically the blood sample is peripheral blood.
[0868] The blood may be further processed before it is contacted with the antibody of the invention. For instance, an anticoagulant, such as citrate (such as sodium citrate),hirudin, heparin, PPACK, or sodium fluoride may be added. Thus, the sample collection container may contain an anticoagulant in order to prevent the blood sample from clotting.
[0869] It will be appreciated that the invention extends to any nucleic acid or peptide or variant, derivative or analogue thereof, which comprises substantially the amino acid or nucleic acid sequences of any of the sequences referred to herein, including variants or fragments thereof. The terms "substantially the amino acid / nucleotide / peptide sequence", "variant" and "fragment", can be a sequence that has at least 40% sequence identity with the amino acid / nucleotide / peptide sequences of any one of the sequences referred to herein, for example 40% identity with any of the sequence identified herein.
[0870] Amino acid / polynucleotide / polypeptide sequences with a sequence identity which is greater than 65%, or greater than 70%, or greater than 75%, or greater than 80% sequence identity to any of the sequences referred to are also envisaged. In some embodiments, the amino acid / polynucleotide / polypeptide sequence has at least 85% identity with any of the sequences referred to, or at least 90% identity, or at least 92% identity, or at least 95% identity, or at least 97% identity, or at least 98% identity, or at least 99% identity with any of the sequences referred to herein.
[0871] The skilled technician will appreciate how to calculate the percentage identity between two amino acid / polynucleotide / polypeptide sequences. In order to calculate the percentage identity between two amino acid / polynucleotide / polypeptide sequences, an alignment of the two sequences must first be prepared, followed by calculation of the sequence identity value. The percentage identity for two sequences may take different values depending on:- (i) the method used to align the sequences, for example, ClustalW, BLAST, FASTA, Smith-Waterman (implemented in different programs), or structural alignment from 3D comparison; and (ii) the parameters used by the alignment method, for example, local vs global alignment, the pair-score matrix used (e.g. BLOSUM62, PAM250, Gonnet etc.), and gap-penalty, e.g. functional form and constants.
[0872] Having made the alignment, there are many different ways of calculating percentage identity between the two sequences. For example, one may divide the number of identities by: (i) the length of shortest sequence; (ii) the length of alignment; (iii) the mean length of sequence; (iv) the number of non-gap positions; or (v) the number of equivalenced positions excluding overhangs. Furthermore, it will be appreciated thatpercentage identity is also strongly length dependent. Therefore, the shorter a pair of sequences is, the higher the sequence identity one may expect to occur by chance.
[0873] Hence, it will be appreciated that the accurate alignment of protein or DNA sequences is a complex process. The popular multiple alignment program ClustalW (Thompson et al., 1994, Nucleic Acids Research, 22, 4673-4680; Thompson etal., 1997, Nucleic Acids Research, 24, 4876-4882) is one way for generating multiple alignments of proteins or DNA in accordance with the invention. Suitable parameters for ClustalW may be as follows: For DNA alignments: Gap Open Penalty = 15.0, Gap Extension Penalty = 6.66, and Matrix = Identity. For protein alignments: Gap Open Penalty = 10.0, Gap Extension Penalty = 0.2, and Matrix = Gonnet. For DNA and Protein alignments: ENDGAP = -1, and GAPDIST = 4. Those skilled in the art will be aware that it may be necessary to vary these and other parameters for optimal sequence alignment.
[0874] In some embodiments, calculation of percentage identities between two amino acid / polynucleotide / polypeptide sequences may then be calculated from such an alignment as (N / T)*100, where N is the number of positions at which the sequences share an identical residue, and T is the total number of positions compared including gaps and either including or excluding overhangs. In some embodiments, overhangs are included in the calculation. Hence, one method for calculating percentage identity between two sequences comprises (i) preparing a sequence alignment using the ClustalW program using a suitable set of parameters, for example, as set out above; and (ii) inserting the values of N and T into the following formula:- Sequence Identity = (N / T)*100.
[0875] Alternative methods for identifying similar sequences will be known to those skilled in the art. For example, a substantially similar nucleotide sequence will be encoded by a sequence which hybridizes to DNA sequences or their complements under stringent conditions. By stringent conditions, the inventors mean the nucleotide hybridises to filter-bound DNA or RNA in 3x sodium chloride / sodium citrate (SSC) at approximately 45°C followed by at least one wash in 0.2x SSC / 0.1% SDS at approximately 20-65°C. Alternatively, a substantially similar polypeptide may differ by at least 1, but less than 5, 10, 20, 50 or 100 amino acids from any of the sequences described herein.
[0876] Due to the degeneracy of the genetic code, it is clear that any nucleic acid sequence described herein could be varied or changed without substantially affecting the sequence of the protein encoded thereby, to provide a functional variant thereof.Suitable nucleotide variants are those having a sequence altered by the substitution of different codons that encode the same amino acid within the sequence, thus producing a silent (synonymous) change. Other suitable variants are those having homologous nucleotide sequences but comprising all, or portions of, sequence, which are altered by the substitution of different codons that encode an amino acid with a side chain of similar biophysical properties to the amino acid it substitutes, to produce a conservative change. For example, small non-polar, hydrophobic amino acids include glycine, alanine, leucine, isoleucine, valine, proline, and methionine. Large non-polar, hydrophobic amino acids include phenylalanine, tryptophan and tyrosine. The polar neutral amino acids include serine, threonine, cysteine, asparagine and glutamine. The positively charged (basic) amino acids include lysine, arginine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. It will therefore be appreciated which amino acids may be replaced with an amino acid having similar biophysical properties, and the skilled technician will know the nucleotide sequences encoding these amino acids.
[0877] All of the features described herein (including any accompanying claims, abstract and drawings), and / or all of the steps of any method or process so disclosed, may be combined with any of the above aspects in any combination, except combinations where at least some of such features and / or steps are mutually exclusive.
[0878] For a better understanding of the invention, and to show how embodiments of the same may be carried into effect, reference will now be made, by way of example, to the accompanying Figures, in which:-
[0879] Figure 1 shows the results from size exclusion chromatography (SEC), coupled to high-performance liquid chromatography (HPLC), of an IL-18 / IL-13 bispecific antibody (BsAb) according to the invention (referred to as "WBP30404_7"), after bispecific antibody assembly (Duobody).
[0880] Figure 2 shows the results from liquid chromatography, coupled to mass spectrometry (LC-MS) screening and purity assessment of an IL-18 / IL-13 bispecific antibody ("WBP30404_7").
[0881] Figure 3 shows the assay conditions and antigens used in the surface plasmon resonance (SPR) measurements to measure affinity for IL-13.Figure 4 shows the kinetic rate constants and affinities of an IL-18 / IL-13 bispecific antibody ("WBP30404_7") to recombinant human IL-13, measured by surface plasmon resonance (SPR).
[0882] Figure 5 shows the assay conditions and antigens used in the surface plasmon resonance (SPR) measurements to measure affinity for IL-18.
[0883] Figure 6 shows the kinetic rate constants and affinities of an IL-18 / IL-13 bispecific antibody ("WBP30404_7") to recombinant human IL-18, measured by surface plasmon resonance (SPR).
[0884] Figure 7 shows the thermal stability assessment of the CH2 and Fab domains of an IL-18 / IL- 13 bispecific antibody ("WBP30404_7").
[0885] Figure 8 shows the results of Affinity-Capture Self-Interaction Nanoparticle Spectroscopy (AC-SINS) to analyse self-interaction and aggregation of an IL-18 / IL-13 bispecific antibody ("WBP30404_7").
[0886] Figure 9 shows the results of hydrophobicity assessment of an IL-18 / IL-13 bispecific antibody ("WBP30404_7") using hydrophobic interaction chromatography (HIC).
[0887] Figure 10 shows the results of determining the isoelectric point of an IL-18 / IL-13 bispecific antibody using imaged capillary isoelectric focusing (icIEF).
[0888] Figure 11 shows the IC50 values for neutralisation of recombinant human IL-18 in KG-1 bioassay with the IL- 18 / IL-13 bispecific antibodies ("WBP30404_7") and an IL-18 monospecific antibody ("WBP30404_10").
[0889] Figure 12 is a table showing the six CDR, VH, VL, CH and CL sequences of the first (IL-18) and second (IL-13) antigen-binding domains of the bispecific antibodies according to the invention. CDR = complementarity determining region; VH = variable heavy chain sequence; VL = variable light chain sequence; CH = constant heavy chain sequence; CL = constant light chain sequence. The sequences are provided using Kabat, Chothia, IMGT and Combined numbering schemes. The Combined numbering scheme is a CDR definition which is based on a combination of the Kabat, Chothia and IMGT numbering schemes. The inventors used technologies including controlled Fabarm exchange (cFAE), Duobody, CrossMab, and WuxiBody to generate these bispecific antibodies. Accordingly, the bispecific antibodies are generated as follows: (i) "Al" IL-18 antigen binding domain (duobody) paired with "Bl" IL-13 antigen binding domain (duobody); (ii) "A2" IL-18 antigen binding domain (CrossMab regular arm) paired with "B2" IL-13 antigen binding domain (CrossMab cross arm); (iii) "A3" IL-18 antigen binding domain (CrossMab cross arm) paired with "B3" IL-13 antigen binding domain (CrossMab regular arm); (iv) "A4" IL-18 antigen binding domain (WuxiBody regular arm) paired with "B4" IL-13 antigen binding domain (WuxiBody Wuxi arm); and (v) "A5" IL-18 antigen binding domain (WuxiBody Wuxi arm) paired with "B5" IL-13 antigen binding domain (WuxiBody regular arm).
[0890] Figure 13 shows exemplary embodiments of the different orientations of the bispecific antibodies according to the invention, generated using CrossMab technology. Orientation 1 = anti-IL-13 VH-VL cross with knob on cross arm; Orientation 2 = anti-IL-13 VH-VL cross with hole on cross arm; Orientation 3 = anti-IL-18 VH-VL cross with knob on cross arm; Orientation 4 = anti-IL-18 VH-VL cross with hole on cross arm; Orientation 5 = anti-IL-13 CH1-CL cross with knob on cross arm; Orientation 6 = anti-IL-13 CH1-CL cross with hole on cross arm; Orientation 7 = anti-IL-18 CH1-CL cross with knob on cross arm; and Orientation 8 = anti-IL-18 CH1-CL cross with hole on cross arm.
[0891] Figure 14 is a table showing the six CDR, VH, VL, CH and CL sequences of the IL-18 affinity matured antibodies according to the invention. The sequences are provided using the Kabat numbering scheme.
[0892] Figure 15 is a table showing the six CDR, VH, VL, CH and CL sequences of the IL-13 affinity matured antibodies according to the invention. The sequences are provided using a Combined numbering scheme (a CDR definition which is based on a combination of the Kabat, Chothia and IMGT numbering schemes).
[0893] Figure 16 is a table showing the six CDR, VH, VL, CH and CL sequences of the first (IL-18) and second (IL-13) antigen-binding domains of the bispecific antibodies according to the invention generated using CrossMab technology. The sequences are provided using a Combined numbering scheme (a CDR definition which is based on a combination of the Kabat, Chothia and IMGT numbering schemes).
[0894] Examples
[0895] IL-18 and IL-13 have been implicated in the pathogenesis of several conditions, such as asthma, allergic rhinitis, atopic dermatitis, fibrosis, and other chronic inflammatory disorders. Therefore, the inventors set out to develop bispecific antibodies that arecapable of specifically binding to, and inhibiting the function of, IL-18 and IL-13, to improve the treatment and diagnosis of these conditions. Additionally, the inventors subjected IL-13 and IL-18 monospecific antibodies to affinity maturation in order to produce novel variants or mutants, with improved binding affinity and functional potency.
[0896] Materials and Methods
[0897] Example 1: Expression of bisoecific constructs
[0898] Fab arm- exchange and in vitro assembly
[0899] One method of producing an IL-18 / IL-13 bispecific antibody is generation from an anti-human IL-18 antibody and an anti-human IL-13 antibody through controlled Fabarm exchange (cFAE) utilizing heterodimerization mutations to control reassembly. To promote Fc heterodimerization, one antibody is engineered with an F405L mutation and the other with a K409R mutation. The two parental antibodies are expressed separately, mixed at equimolar ratios, and subjected to mild reducing conditions to allow Fab-arm exchange. Upon removal of the reducing agent, inter-heavy chain disulfide bonds reform, stabilizing the heterodimeric bispecific antibody.
[0900] CrossMab expression
[0901] One method of producing an IL-18 / IL-13 bispecific antibody is wherein one Fab arm retains a conventional heavy chain / light chain pairing, and the second arm contains a variable domains which have been swapped at the molecular level to promote correct chain pairing. The Fc has been engineered for heterodimerization with one arm using a 'knob' mutation (T366W) and 'hole' mutations (T366S, L368A, Y407V) on the other arm. Co-transfection of the four plasmids encoding the individual chains was carried out in mammalian cells. Purification was performed using standard techniques.
[0902] Molecule quality was tested using biophysical techniques, including SEC-HPLC and LC-MS.
[0903] Wuxibody expression
[0904] One method of producing and IL-18 / IL-13 bispecific antibody is wherein wherein one Fab arm comprises immunoglobulin (IgG) constant domains and the other Fab arm comprises engineered human TCR constant domains (Co / CP), enabling orthogonal heavy / light chain pairing. The Fc has been engineered for heterodimerization with one arm using a 'knob' mutation (T366W) and 'hole' mutations (T366S, L368A, Y407V) on the other arm. Co-transfection of the four plasmids encoding the individual chains was carried out in mammalian cells. Purification was performed using standard techniques.Molecule quality was tested using biophysical techniques, including SEC-HPLC and LC-MS.
[0905] SEC-HPLC
[0906] Size exclusion chromatography, coupled to HPLC, is a purity method that separates molecules based on their size or hydrodynamic volume. This method is particularly effective for the analysis of aggregates, monomer and low-molecular-weight (LWM) and was used to monitor antibody quality after re-assembly. SEC analysis was performed with HPLC with a TSKgel G3000SWxl stainless steel column (7.8 x 300 mm).
[0907] The yield of the re-assembly reaction was also calculated by the following equation: total input amount (mg) / final amount (mg) x 100.
[0908] The IL-18 / IL-13 bispecific antibody (Duobody) had a yield of 100% after purification by MSS-SEC-Reduction-Dialysis-CEX (Figure 1).
[0909] LC-MS
[0910] Size exclusion chromatography, coupled to HPLC, is a purity method that separates molecules based on their size or hydrodynamic volume. This method is particularly effective for the analysis of aggregates, monomer and low-molecular-weight (LWM) and was used to monitor antibody quality after re-assembly. SEC analysis was performed with HPLC with a TSKgel G3000SWxl stainless steel column (7.8 x 300 mm).
[0911] WBP30404_7 had 91.0% of isoforms with the expected mass after in vitro assembly (Figure 2).
[0912] Example 2: Affinities to recombinant human IL-18 and IL-13 measured by SPR Kinetic binding parameters were determined using surface plasmon resonance (SPR) measurements on the Biacore™ T200 (Cytiva Life Sciences). This technique enables the label-free measurement of the kinetic rate constants for binding (ka, association rate constant) and dissociation (kd, dissociation rate constant) between a ligand and an antibody. The equilibrium dissociation constant, KD, is derived from these kinetic rate constants.
[0913] To measure the affinity of the bispecific antibody for human IL-13, the surface of a CM5 sensor chip was prepared for binding of the antibodies. Antibodies were dilutedinto blank buffer (HBS-EP+) to a final concentration of 4.8 or 12.4nM. Affinity measurements were the determination of kinetic constants were performed for IL-13 (R8iD Systems Cat#213-ILB / CF) tested in a DR starting at 20nM. The flow cell was kept at a temperature of 25°C (Table of assay conditions and antigens used is also shown in Figure 3). To measure the affinity of the bispecific antibody for human IL-18, the surface of a protein A sensor chip was prepared for binding of the antibodies. Antibodies were diluted into blank buffer (PBS-P+) to a final concentration of 5nM. Affinity measurements were the determination of kinetic constants were performed for IL-18 (MBL Cat#B001-5 lot#130) tested in a DR starting at 15nM. The flow cell was kept at a temperature of 37°C (Table of assay conditions and antigens used is also shown in Figure 5). The trace, ka, kd and KD values obtained are shown in Figures 4 and 6.
[0914] Example 3: Differential scanning fluorimetrv (DSF) to enable thermal stability assessment of the CH2 and Fab domains of IL-18 / IL-13 bispecific antibodies
[0915] DSF estimates the temperature of the protein unfolding transition (Tm) by measuring the change in the fluorescence intensity of an environmentally sensitive fluorophore added to the solution. Such molecules display low fluorescence in a hydrophilic environment. In most folded proteins, hydrophobic regions are sequestered from the solution within the protein core. During denaturation, proteins lose their tertiary and secondary structures leading to exposure of the hydrophobic regions. These regions can bind an environmentally sensitive dye leading to an increase in its fluorescence.
[0916] The bispecific mAbs were diluted to 0.1 mg / mL in PBS pH 7.5. SYPRO Orange was diluted 1000-fold from the 5000x concentrated stock to the working dye solution in the appropriate buffer prior to addition to the samples. Thermal denaturation was carried out using CFX96 Touch Real-Time PCR Detection System (BioRad) increasing the temperature. Fluorescence intensity was collected and analysed using the first derivative approach, to calculate Tm. Two replicates were collected for each molecule. In this method, Tm is the temperature corresponding to the maximum value of the first derivative of the DSF melting curve. Delta Tm values (ATm) for various formulation buffers were calculated by subtracting the Tm value obtained for mAbl in a reference formulation from the Tm value obtained for mAbl in the tested formulation.
[0917] The melting temperatures of the CH2 and Fab domains of the bispecific antibodies are shown in Figure 7.Example 4:
[0918]
[0919] re Self-Interaction
[0920]
[0921] Antibodies are adsorbed onto gold nanoparticles to generate a high local protein concentration that mimics concentrated antibody solutions. The attractive selfinteraction reduces the interparticle distance between immobilized antibodies, which leads to a red-shift of the wavelength of maximum absorbance. Anti-human Fc and whole IgG antibodies were prepared in acetate buffer and mixed at defined concentrations with colloidal gold nanoparticles. After incubation and centrifugation, monoclonal antibody test samples were diluted in buffer and combined with the nanoparticle suspension to achieve target concentrations of antibody, gold conjugate, and PEG2000. Samples were mixed, incubated, and gently centrifuged. Absorbance spectra (450-700 nm) were measured using a SpectraMax M2e, (Molecular Devices) plate reader and analysed with curve-fitting software. A plasmon wavelength shift greater than 10 nm indicated potential self-associati...
Claims
Claims1. A bispecific antibody or antigen-binding fragment thereof, comprising a first antigen-binding domain that specifically binds to Interleukin-18 (IL-18) or a functional fragment or variant thereof, and a second antigen-binding domain that specifically binds to Interleukin-13 (IL-13) or a functional fragment or variant thereof.
2. The bispecific antibody or antigen-binding fragment thereof according to claim 1, wherein the bispecific antibody or antigen-binding fragment thereof binds to one or more amino acids within a sequence comprising or consisting of a sequence as substantially set out in SEQ ID No: 42 and / or SEQ ID No: 43, or a functional fragment or variant thereof.
3. The bispecific antibody or antigen-binding fragment thereof according to claim 1 or claim 2, wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 58, a CDR-H2 domain comprising or consisting of SEQ ID No: 50, a CDR-H3 domain comprising or consisting of SEQ ID No: 51, a CDR-L1 domain comprising or consisting of SEQ ID No: 44, a CDR-L2 domain comprising or consisting of SEQ ID No: 45, and a CDR-L3 domain comprising or consisting of SEQ ID No: 46; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
4. The bispecific antibody or antigen-binding fragment thereof according to claim 1 or claim 2:(a) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 58, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 119, a CDR-H2 domain comprising or consisting of SEQ ID No: 120, a CDR-H3 domain comprising or consisting of SEQ ID No: 121, a CDR-L1 domain comprising or consisting of SEQ IDNo: 114, a CDR-L2 domain comprising or consisting of SEQ ID No: 115, and a CDR-L3 domain comprising or consisting of SEQ ID No: 116; ; or(b) wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 44, a CDR-H2 domain comprising or consisting of SEQ ID No: 45, a CDR-H3 domain comprising or consisting of SEQ ID No: 46, a CDR-L1 domain comprising or consisting of SEQ ID No: 58, a CDR-L2 domain comprising or consisting of SEQ ID No: 50, and a CDR-L3 domain comprising or consisting of SEQ ID No: 51; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 114, a CDR-H2 domain comprising or consisting of SEQ ID No: 115, a CDR-H3 domain comprising or consisting of SEQ ID No: 116, a CDR-L1 domain comprising or consisting of SEQ ID No: 119, a CDR-L2 domain comprising or consisting of SEQ ID No: 120, and a CDR-L3 domain comprising or consisting of SEQ ID No: 121.
5. The bispecific antibody or antigen-binding fragment thereof according to claim 1 or claim 2, wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
6. The bispecific antibody or antigen-binding fragment thereof according to claim 1 or claim 2, wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-H2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, a CDR-H3 domain comprising or consisting of SEQ ID No: 3 or 8, a CDR-L1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-L2 domain comprising or consisting of SEQ ID No: 10 or 13, and a CDR-L3 domain comprising or consisting of SEQ ID No: 11; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-H2 domain comprising or consisting of SEQ ID No: 34 or 37, a CDR-H3 domain comprising or consisting of SEQ ID No: 35, a CDR-L1 domain comprising or consistingof SEQ ID No: 24, 27, 29 or 32, a CDR-L2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, and a CDR-L3 domain comprising or consisting of SEQ ID No: 26 or 31.
7. The bispecific antibody or antigen-binding fragment thereof according to claim 1 or claim 2, wherein (i) the first antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 9 or 12, a CDR-H2 domain comprising or consisting of SEQ ID No: 10 or 13, a CDR-H3 domain comprising or consisting of SEQ ID No: 11, a CDR-L1 domain comprising or consisting of SEQ ID No: 1, 4 or 6, a CDR-L2 domain comprising or consisting of SEQ ID No: 2, 5 or 7, and a CDR-L3 domain comprising or consisting of SEQ ID No: 3 or 8; and (ii) the second antigen-binding domain comprises a CDR-H1 domain comprising or consisting of SEQ ID No: 24, 27 , 29 or 32, a CDR-H2 domain comprising or consisting of SEQ ID No: 25, 28 or 30, a CDR-H3 domain comprising or consisting of SEQ ID No: 26 or 31, a CDR-L1 domain comprising or consisting of SEQ ID No: 33 or 36, a CDR-L2 domain comprising or consisting of SEQ ID No: 34 or 37, and a CDR-L3 domain comprising or consisting of SEQ ID No: 35.
8. The bispecific antibody or antigen-binding fragment thereof according to claim 3, wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 59, and a light chain variable region comprising or consisting of SEQ ID No: 47; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
9. The bispecific antibody or antigen-binding fragment thereof according to claim 4:(a) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 59; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 122, and a light chain variable region comprising or consisting of SEQ ID No: 117; or(b) wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 47, and a light chain variable region comprising or consisting of SEQ ID No: 59; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 117, and a light chain variable region comprising or consisting of SEQ ID No: 122.
10. The bispecific antibody or antigen-binding fragment thereof according to claim 5, wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.
11. The bispecific antibody or antigen-binding fragment thereof according to claim 6, wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 39, and a light chain variable region comprising or consisting of SEQ ID No: 38.
12. The bispecific antibody or antigen-binding fragment thereof according to claim 7, wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 15, and a light chain variable region comprising or consisting of SEQ ID No: 14; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.
13. The bispecific antibody or antigen-binding fragment thereof according to claim 5, wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 14, and a light chain variable region comprising or consisting of SEQ ID No: 15; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 40, and a light chain variable region comprising or consisting of SEQ ID No: 39.
14. The bispecific antibody or antigen-binding fragment thereof according to claim 5, wherein (i) the first antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 16, and a light chain variable region comprising or consisting of SEQ ID No: 15; and (ii) the second antigen-binding domain comprises a heavy chain variable region comprising or consisting of SEQ ID No: 38, and a light chain variable region comprising or consisting of SEQ ID No: 39.
15. The bispecific antibody or antigen-binding fragment thereof according to any preceding claim, wherein the bispecific antibody or antigen-binding fragment thereof comprises a mutated Fc fragment, optionally wherein:(i) the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: L234A, L235A, and P329G, according to EU numbering;(ii) the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: N325S and L328F, according to EU numbering;(iii) the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: M252Y, S254T, and T256E, according to EU numbering;(iv) the Fc fragment comprises one or more amino acid substitution selected from the group consisting of: L234F, L235E and P331S, according to EU numbering;(v) the Fc fragment of the first or second antigen-binding domain comprises a T366W amino acid substitution, and the Fc fragment of the first or second antigenbinding domain comprises the amino acid substitutions T366S, L368A, and Y407V, according to EU numbering; and / or(vi) the Fc fragment of the first or second antigen-binding domain comprises a F405L amino acid substitution, and the Fc fragment of the first or second antigenbinding domain comprises a K409R amino acid substitution, according to EU numbering.
16. An antibody or antigen-binding fragment thereof that specifically binds to IL-18, and comprises:(i) a CDR-H1 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 44, 80, 84, 101, 104, or 114, or a variant or fragment thereof;(ii) a CDR-H2 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 45, 56, 62, 64, 68, 70, 72, 78, 82, 86, 88, 90, 102, or 115, or a variant or fragment thereof;(iii) a CDR-H3 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 46, 60, 106, or 116, or a variant or fragment thereof;(iv) a CDR-L1 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 49, 54, 58, 74, or 119, or a variant or fragment thereof;(v) a CDR-L2 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 50, 93, or 120, or a variant or fragment thereof; and / or(vi) a CDR-L3 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 51, 76, 94, 108, or 121, or a variant or fragment thereof.
17. The antibody or antigen-binding fragment thereof according to claim 16, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising or consisting of any one of SEQ ID Nos: 47, 57, 61, 63, 65, 69, 71, 73, 79, 81, 83, 85, 87, 89, 91, 92, 97, 98, 103, 105, 107, 110, 112, 113, or 117, and a light chain variable region comprising or consisting of any one of SEQ ID Nos: 52, 55, 59, 67, 75, 77, 95, 96, 100, 109, 111, or 122.
18. An antibody or antigen-binding fragment thereof that specifically binds to IL-13, and comprises:(i) a CDR-H1 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 114 or 131, or a variant or fragment thereof;(ii) a CDR-H2 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 123 or 115, or a variant or fragment thereof;(iii) a CDR-H3 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 116 or 129, or a variant or fragment thereof;(iv) a CDR-L1 domain comprising or consisting of a sequence as substantially set out in any one of SEQ ID Nos: 125, 127, or 133, or a variant or fragment thereof;(v) a CDR-L2 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 120, or a variant or fragment thereof; and / or (vi) a CDR-L3 domain comprising or consisting of a sequence as substantially set out in SEQ ID No: 121, or a variant or fragment thereof.
19. The antibody or antigen-binding fragment thereof according to claim 18, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising or consisting of any one of SEQ ID Nos: 124, 130, or 132, and a light chain variable region comprising or consisting of any one of SEQ ID Nos: 126, 128, or 134.
20. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 1 to 15, or the antibody or antigen-binding fragment thereof according to any one of claims 16 to 19, for use in therapy.
21. The bispecific antibody or antigen-binding fragment thereof according to any one of claims 1 to 15, or the antibody or antigen-binding fragment thereof accordingto any one of claims 16 to 19, for use in treating, preventing or ameliorating a condition mediated by IL-18 and / or IL-13.
22. The bispecific antibody or antigen-binding fragment thereof, or the antibody or antigen-binding fragment thereof, for use according to claim 21, wherein the condition mediated by IL-18 and / or IL-13 is selected from the group consisting of: Atopic Dermatitis (AD I Eczema), Systemic Juvenile Idiopathic Arthritis (sJIA), Adult-Onset Still's Disease (AOSD), Macrophage Activation Syndrome (MAS), Hemophagocytic Lymphohistiocytosis (HLH), Inflammatory Bowel Disease (IBD) including Crohn's Disease and Ulcerative Colitis, Multiple Sclerosis (MS), Neuroinflammation, Alzheimer's Disease, Chronic Obstructive Pulmonary Disease (COPD), Asthma including Allergic Asthma, Allergic Rhinitis (Hay Fever), Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Urticaria (Chronic Hives), Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Eosinophilic Pneumonia, Systemic Lupus Erythematosus (SLE), Primary Sjogren's Syndrome, Hypereosinophilic Syndrome (HES), Pemphigus, Psoriasis, Ankylosing Spondylitis, Rheumatoid Arthritis (RA), Fibrosis including Pulmonary Fibrosis and Liver Fibrosis, Infections, Sepsis, and Cytokine Storm Syndromes.
23. A pharmaceutical composition comprising the bispecific antibody or antigenbinding fragment thereof according to any one of claims 1 to 15, or the antibody or antigen-binding fragment thereof according to any one of claims 16 to 19, and optionally a pharmaceutically acceptable vehicle.
24. A process for making the pharmaceutical composition according to claim 23, the process comprising combining a therapeutically effective amount of the bispecific antibody or antigen-binding fragment thereof according to any one of claims 1 to 15, or the antibody or antigen-binding fragment thereof according to any one of claims 16 to 19, with a pharmaceutically acceptable vehicle.
25. One or more polynucleotide sequence encoding the bispecific antibody or antigen binding fragment thereof according to any one of claims 1 to 15, or the antibody or antigen-binding fragment thereof according to any one of claims 16 to 19.
26. An expression cassette comprising one or more polynucleotide sequence according to claim 25.
27. A recombinant vector comprising the expression cassette according to claim28. A host cell comprising the one or more polynucleotide sequence according to claim 25, the expression cassette according to claim 26, or the vector according to claim 27.
29. A method of preparing the bispecific antibody or antigen binding fragment according to any one of claims 1 to 15, or the antibody or antigen-binding fragment thereof according to any one of claims 16 to 19, the method comprising:a) introducing, into a host cell, the vector of claim 27; andb) culturing the host cell under conditions to result in the production of the bispecific antibody or antigen binding fragment according to any one of claims 1 to 15, or the antibody or antigen-binding fragment thereof according to any one of claims 16 to 19.
30. The bispecific antibody or antigen-binding fragment according to any one of claims 1 to 15, or the antibody or antigen-binding fragment thereof according to any one of claims 16 to 19, for use in diagnosis or prognosis.
31. The bispecific antibody or antigen-binding fragment according to any one of claims 1 to 15, or the antibody or antigen-binding fragment thereof according to any one of claims 16 to 19, for use in diagnosing or prognosing a condition mediated by IL-18 and / or IL-13.
32. A method of diagnosing or prognosing a condition mediated by IL-18 and / or IL-13 in a subject, the method comprising detecting IL-18 and / or IL-13 in a biological sample obtained from the subject with the bispecific antibody or antigen-binding fragment according to any one of claims 1 to 15, or the antibody or antigen-binding fragment thereof according to any one of claims 16 to 19.
33. A kit for diagnosing a subject suffering from a condition mediated by IL-18 and / or IL-13, or for providing a prognosis of the subject's condition, the kit comprising the bispecific antibody or antigen-binding fragment thereof according to any one of claims 1 to 15, or the antibody or antigen-binding fragment thereof according to any one of claims 16 to 19, for detecting IL-18 and / or IL-13 in a sample from a test subject.
